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Abstracts of Invited Paperst
Symposium on Lung Cancer
The endocrinology of lung cancer
K. Havemann & G. Bepler
Department ofMedicine, Division ofHematology/Oncology,
University ofMarburg, 3550 Marburg, FRG.
Small cell lung cancer (SCLC) is thought to be derived from
neuroendocrine cells of the bronchopulmonary tract. This
assumption is based on morphological features, i.e. dense
core vesicles, and biochemical characteristics, i.e. the
production of neuroendocrine peptides and the expression of
enzymes of the diffuse neuroendocrine system. As a result,
SCLC has been classified as a malignant neuroendocrine
tumour of the lung. We have studied the production of
bombesin, neurotensin, calcitonin, calcitonin gene-related
peptide (CGRP), somatostatin and tachykinins in 12 SCLC
and 8 non-SCLC cell lines. Bombesin, neurotensin,
calcitonin, CGRP, somatostatin and tachykinins were
produced by some but not all SCLC cell lines. Non-SCLC
lines had undetectable levels. Neuroendocrine enzymatical
markers such as NSE or CK-BB were present in all lung
cancer cell lines but significantly higher in SCLC. Specific
membrane binding sites for bombesin and calcitonin were
found in SCLC but not in non-SCLC cell lines. The
production of peptides and expression of membrane binding
sites suggest an autocrine effect on tumour growth. The
peptides were thus screened for their growth in liquid culture
and semi-solid agarose culture using serum-free techniques.
Bombesin was found to stimulate the growth of 8
independent SCLC cell lines in a serum-free cloning system
only. This effect was absent in the presence of a bombesin
receptor antagonist. In addition, we evaluate the usefulness
of calcitonin, neurotensin, NSE and CK-BB as tumour
markers in sera of SCLC patients who entered a prospective
multicentre trial. Our results indicate that the levels of the
peptide and enzyme markers correlate with tumour spread,
prognosis, and early response to therapy.
The cell surface in lung cancer
J. Bergh
Department ofOncology, University of Uppsala, S-751 85
Uppsala, Sweden.
Human small cell carcinoma of the lung (SCCL) is
*BACR enquiries to: BACR Secretariat, c/o Institute of Biology,
20 Queensberry Place, London SW7 2DZ.
tReprints of these abstracts are not available - Ed.
characterized by a spectrum of neuroendocrine markers.
Non-SCCL on the other hand is deprived of these
characteristics, or express them in low quantities. The cell
surface is of major importance for inter- and intracellular
communications via specific receptors and transport
mechanisms. The surface membrane is composed of a vast
number of glycoproteins (GP) and glycolipids (GL), but
their specific functions are still mainly unknown.
The descriptive analyses of the surface GP using the
galactose-oxidase tritiated sodium borohydride technique
and 1251 labelling techniques have demonstrated that SCCL
expresses a different pattern of surface GP as compared to
non-SCCL. The principal patterns of these GP also seem to
remain unaltered during prolonged in vitro cultivation and
upon growth in defined medium. The surface GL of SCCLs
contain a specific monosialoganglioside, fucosyl-GMI, and 2-
hydroxy-fatty acids as major gangliosides in high frequency
of examined biopsies. In contradistinction to the surface GP,
these 'specific' GL seem to be altered during prolonged in
vitro cultivation of SCCL cell lines.
Lung tumour markers
J.G. Reeve
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
Much research has been devoted to the biochemistry of lung
cancer cells with a view to identifying markers for clinical
application and for tracing cell lineage relationships between
the major forms of lung cancer. The endocrine status of
small cell lung cancer (SCLC) has led to the evaluation of
peptide and non-peptide hormones, enzymes and structural
proteins as diagnostic markers for the SCLC phenotype.
However, it is now generally accepted that many of these
substances are associated with all the histological types of
bronchogenic carcinoma. Whilst the presence or absence of a
given biochemical marker may be of little diagnostic value,
certain biomarkers may be useful for monitoring therapy
particularly in patients with SCLC where a relationship
between tumour burden and levels of NSE, calcitonin and
ACTH has been demonstrated. However, there exists no
single marker for which elevated levels can be measured in
all patients with lung cancer and in many recurrences,
markers rise indistinctly or too late to be clinically useful, or
not at all. The search for reliable lung tumour markers has
prompted many groups to develop monoclonal antibodies
(MoAbs) to membrane determinants. A number of MoAbs
now exist which are histologically type-specific and others
recognise antigens common to SCLC and non-SCLC,
perhaps defining a phenotypic link between these two
histologies. Many MoAbs fail to fulfil the clinical objectives
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for which they were developed. However, several are likely
to be of diagnostic value, some detect shed tumour-antigens
and may be of value in monitoring therapy and others are
selectively cytotoxic to tumour cells bearing the defined
antigen or are antiproliferative. In some cases clinical
evaluation of such MoAbs is in progress.
Genetic predisposition to human lung cancer
J. Heighway
Paterson Institute for Cancer Research, Christie Hospital,
Manchester M20 9BX, UK.
A restriction fragment length polymorphism (RFLP) has
been shown to be associated with the human c-Ha-ras gene.
The RFLP has been shown to result from the variation in
size of a region of repetitive DNA, approximately lkb 3' of
the polyadenylation signal of the gene. Four common alleles
have been identified (al to a4) with occasional rare variants
and Krontiris et al (1985) Nature 313, 369 suggested that
rare alleles predisposed an individual to cancer.
The c-Ha-ras allele frequency has been studied in a group
of lung cancer patients and unaffected controls. The patients
were divided into two groups (a) individuals with small cell
carcinoma (SCCL) (b) those with non-small cell carcinoma
(N-SCCL). No significant variation in the frequency of rare
alleles was found between the groups of cancer patients and
unaffected controls. However a significant difference in the
frequency of one allele (a4) was found between individuals
with N-SCCL and unaffected controls (P<0.05) and
between those with N-SCCL and SCCL (P<0.004) This
suggests a degree of genetic predisposition to N-SCCL.
6th Alexander Haddow Memorial Lecture
The molecular biology of lung cancer
J. Minna
NCI-Navy Medical Oncology Branch, US National Cancer
Institute, Bethesda, USA.
Molecular genetic studies on a large panel of human small
cell lung cancer (SCLC) lines have revealed a consistent set
of abnormalities that could potentially explain part or all of
the malignant phenotype of these cells. First, restriction
fragment polymorphism analysis (by Dr S. Naylor, Univ.
Texas) has demonstrated that the cytogenetic deletion of
chromosome region 3p (14-23) represents a true DNA
deletion. This suggests SCLC may have similar genetic
mechanisms operating, as those in retinoblastoma and
Wilm's tumours. Second, frequently we have found
amplification or deregulated expression of the myc family of
oncogenes (including c-, N-, and L-myc) as well as
expression of the p53 proto-oncogene. The structure and
expression of L-myc are particularly interesting as alternative
processing of L-myc mRNA is seen in both small cell and
non-small cell lung cancer groups. This alternative processing
generates messages with different combinations of the 2nd
and 3rd exon myc family equivalents, a feature not yet
described for c-myc or N-myc. In addition, expression of
cellular proto-oncogenes of the ras and raf(studies by Dr U.
Rapp, NCI) families in these same cells set the stage for
oncogene cooperation. Finally, it appears that both SCLC
and non-SCLC lines can replicate in serum- and hormone-
free medium for prolonged periods of time indicating their
ability either to produce autocrine growth factors (such as
gastrin releasing peptide) or subvert intracellular transducing
signals to function in an autocrine fashion. (Abstract only.)
The current status of anti-smoking measures in the UK
D. Simpson
Action and Smoking and Health, 5-11 Mortimer Street,
London WIN 7RH, UK.
Despite having led the world in the epidemiology of smoking
and still having the highest death rate from lung cancer in
the world, the UK has a far from satisfactory record in the
implementation of effective anti-smoking measures. It was
one of the first countries to implement such measures, but
still has no overall government policy on smoking and the
health department policy is not comprehensive and falls far
short of standards set by WHO, UICC, the Royal College of
Physicians and other agencies. Nevertheless, the present
decline in consumption is among the fastest in the world. An
ideal smoking control policy includes action in the areas of
health education, public information, tobacco promotion,
smoking in public places, taxation and the reduction of
emission levels of tar, carbon monoxide and nicotine.
Outstanding in recent years has been the UK's performance
on the increase of the real price of cigarettes by means of
regular tax rises. Performance has been disappointing,
however, in restricting advertising and other forms of
promotion in public places, both energetically resisted by the
tobacco industry. Health education has been low in status,
priority and expenditure but public information work
through the news media has been comparatively successful.
Advances in the clinical therapy of lung cancer
R.L. Souhami
Department ofRadiotherapy and Oncology, University College
Hospital, Gower Street, London WCIE 6AU, UK.
Combination chemotherapy has improved median survival in
small cell lung cancer (SCLC) but the proportion of patients
surviving beyond 2 years is less than 10%. Attempts to
improve results by alternating drug regimens have not been
successful, but active new agents such as carboplatin,
ifosfamide and VM26 have yet to be incorporated into
multiagent regimens. The optimum duration of combination
chemotherapy has not been determined. Recent studies have
identified patients who have a greater than 25% chance of
survival beyond 2 years, in whom intensification of
chemotherapy may increase cure rate. Patients with multiple
adverse prognostic factors may have their survival shortened
by the use of combination chemotherapy. Such patients can
be identified and alternative treatment strategies designed to
minimise toxicity, can be developed. Mediastinal irradiation
may benefit a small number of patients who have a complete
response to chemotherapy. Prophylactic cranial irradiation
does not appear to prolong survival but may be justified by
the unpleasant consequences of brain metastasis.
In non small cell lung cancer (NSCLC) it is not known
whether mediastinal irradiation improves the prognosis of
patients with resectable tumours but who have mediastinal
node involvement. In advanced NSCLC there is a lack of
effective drugs but response rates of 20-30% can be achieved
with several combinations. There is no overall survival
benefit from chemotherapy, but patients can be identified
who have a greater chance of response and it remains to be
shown if they benefit from treatment.JOINT MEETING OF THE BACR, EACR AND THE RSM 333
Symposium on Lymphoma Phenotypes of anaplastic large cell lymphomas
G. Delsol
Retroviruses and lymphoma Department ofPathology, CHU Purpan, Toulouse 31059,
France. R.A. Weiss
Institute ofCancer Research: Royal Cancer Hospital, Chester
Beatty Laboratories, Fulham Road, London SW3 6JB, UK.
Retroviruses are well known aetiological agents of
lymphoma in fish, birds and mammals. Since 1980,
retroviruses have been identified in association with
lymphoma in man. Human T-cell leukaemia virus type I
(HTLV-I) is the principal cause of adult T-cell leukaemia-
lymphoma (ATLL), a malignancy of mature T4 lymphocytes
prevalent in Japan and the Caribbean. Lymphomas are also
the second commonest tumour in AIDS, a syndrome caused
by another kind of retrovirus, the human immunodeficiency
virus type (HIV-1). In ATLL, the retrovirus directly induces
T-cell transformation leading to eventual malignancy,
whereas in AIDS, the lymphomas are generally EBV-positive
B-cell neoplasms probably arising as a result of immuno-
suppression induced by HIV-1. Current ideas on the
molecular mechanisms of cell transformation and immuno-
suppression by human retroviruses will be reviewed.
Epstein-Barr virus and lymphoma
A.B. Rickinson
Department of Cancer Studies, University ofBirmingham
Medical School, Birmingham, B15 2TJ, UK.
Epstein-Barr virus (EBV)-associated lymphomas can now be
divided into two categories. The EBV-positive lympho-
proliferations seen most commonly in immunosuppressed
transplant patients are oligoclonal, carry no specific
chromosomal translocations and appear, from clinical
evidence, to remain sensitive to virus-specific T cell control;
experimental EBV infection of cotton-top marmosets induces
a very similar disease. By contrast EBV-positive Burkitt's
lymphomas (BL) seen most commonly in equatorial Africa
(but occurring worldwide) are monoclonal, carry specific
translocations leading to constitutional activation of the c-
myc gene, and are usually not recognised by virus-specific T
cell surveillance.
We believe these differences relate in part to the separate
identities of the target cells involved, and to their different
interactions with the virus. In particular surface marker
analysis of BL biopsies has revealed a homogeneous BL cell
phenotype positive for pan B markers, for CDIO (cALLA)
and for the tumour-associated glycolipid antigen BLA, but
negative for the various B cell activation antigens seen on all
normal EBV-transformed lymphoblastoid cell lines (LCLs).
It is significant that tumour cell lines which retain the BL
cell phenotype in vitro show a unique pattern of expression
of EBV latent genes which is more restricted than that
shown in LCLs. This new form of infection may be a unique
feature of the malignant cells or may reflect the usual
interaction of the virus with the particular B cell subset from
which BL arises. We have now identified and isolated a
normal tonsillar B cell subpopulation with the same cell
surface phenotype as the tumours and are studying its
interaction with EBV.
Among large cell lymphomas, a distinctive group of 65 cases
with very large anaplastic cells, often unfiltrating the lymph
node sinuses, was identified. According to the reactivity of
these tumours with monoclonal antibodies (MoAbs) detect-
ing epithelial membrane antigen (EMA) and the recently des-
cribed Kil antigen, four subtypes could be distinguished. In
the majority of cases (n=48), neoplastic cells were found to
coexpress EMA and Kil antigen. All the cases studied on
frozen sections also proved to be positive for three anti-Tac
antibodies (type 1: EMA+, Ki+, Tac+). In the second type
(n=7) neoplastic cells expressed Kil antigen but were
unreactive with the anti-EMA and anti-Tac MoAbs (type 2:
EMA-, Kil+, Tac-). There were also tumours with
similar morphology expressing only EMA (type 3: EMA+,
Kil-, Tac?) (n=4) or with an EMA-, Kil-, Tac-
phenotype (type 4: 6 cases). Whether these various
phenotypes have prognostic significance cannot yet be
determined. MoAbs identifying T, B, or macrophage-
associated antigens showed that these cases were hetero-
geneous in terms of cell lineage. However, for the tumours
coexpressing EMA, Kil and Tac antigens the commonest
origin was T cell (15 cases), no definite cell lineage could be
attributed to 11 cases; only 3 cases showed B cell markers
and 3 other cases displayed a mixed T/B phenotype. By
contrast, tumours of type 2, 3 or 4 were mainly developed
from B cells (n =10) or showed a mixed B/T (n =2) or nul
(n =2) phenotype. Although morphological characteristics of
the majority of cases were consistent with the diagnosis of
malignant histiocytosis, double immunoenzymatic staining
showed clearly that EMA +, Kil+ neoplastic cells were
unreactive with anti-macrophage antibodies. These results
confirm that true malignant histiocytoses are very rare.
Growth factors and their receptors
T.M. Dexter
Paterson Institute for Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
7th Gordon Hamilton-Fairley Memorial
Lecture
Oncogene activation by chromosomal translocation in
carcinogenesis
G. Klein
Department of Tumour Biology, Karolinska Institutet,
Box 60400, S-104 01 Stockhom, Sweden.
Current evidence concerning the mechanism of oncogene
activation by chromosomal translocations and its role in
various forms of tumorigenesis will be reviewed. Specific
attention will be devoted to the role of the c-myc/Ig
juxtaposition in the genesis of Burkitt lymphoma, mouse
plasmacytoma and rat immunocytoma. The following
aspects will be discussed: (i) Does the cis-relationship
between the c-myc oncogene and one of the 3 Ig-loci play a
causative role in the genesis of these tumours? (ii) How does
the juxtaposition activate the myc-gene? (iii) What is the334 JOINT MEETING OF THE BACR, EACR AND THE RSM
functional role of the translocation in the tumorigenic
process?
In BL, the translocation has been found in 100% of the
properly investigated cases so far, with no difference between
endemic or nonendemic, EBV carrying or EBV negative
cases. In MPC, only - 90% of the MPCs carry the
translocations. Cytogenetic and molecular examination of
the exceptional tumours has revealed, however, that they
carry cryptic Ig-myc juxtapositions. The regularity of the
association between the translocation events and the tumours
where they occur, together with the analogy between the 3
systems can only be interpreted by postulating that the
activation of c-myc by the translocation represents an
essential step in the genesis of BL, MPC and RIC. A
hypothesis will be presented to explain the way in which the
constitutive myc activation contributes to the escape of the
tumour precursor cells from immune and non immune
controls. (Abstract only.)
Gene probing as a criterion of monoclonality
K. Thielemans
Division ofHematology and Immunology, Medical School of
the Free University ofBrussels (VUB), 1090 Brussels,
Belgium.
A molecular genetics approach to the diagnosis of lymphoid
proliferative disorders, providing a sensitive marker for
clonality as well as for lineage assignment (B vs. T
lymphocytes) in neoplasms lacking definitive phenotypic
markers, has been developed recently. This approach relies
on detecting uniform rearrangements of the genes coding the
antigen recognition molecules of B cells (immunoglobulin)
and T cells (T cell receptor) within clonal proliferations. The
analysis of the Ig and TCR genes by Southern blot
hybridisation has great potential for complementing
conventional marker analysis, cytogenetics and histo-
pathology in the definition, classification and diagnosis of
lymphoproliferative disorders. It becomes a useful tool with
which to follow the patient's therapeutic response and
monitor the patient's clinical course for early signs of
relapse. Molecular genetic analysis, in association with
cytogenetics and immunology, can provide important
insights into the immunobiology and oncogenesis of
lymphoid cancer.
The non-Hodgkin lymphomas (NHDL) - Deciding on
chemotherapy
J.M.A. Whitehouse
CRC Wessex Medical Oncology Unit, Southampton
General Hospital, Southampton S09 4XY, UK.
The clinical behaviour of patients with NHDL is indicative
of different pathologies rather than a single disease type. The
relationship between morphological characteristics and the
natural history of broad sub-types supports the existence of
distinct entities. A classification of the non-Hodgkin
lymphomas based on morphological characteristics, having
precise and reproducible clinical relevance has not yet
emerged, but the National Cancer Institute Working
Formulation offers a reasonable compromise for inter-
national use. Clinical studies have for some time identified
variations in behaviour and therapeutic outcome in patients
with apparently similar disease extent and histologies.
Immunological studies and, more recently, the use of DNA
probes have underlined the heterogeneity of some groups
which are apparently well defined morphologically. It seems
likely that further sub-categories of NHDL will eventually
emerge based on the application of these approaches. Such
precise definition may contribute to a better understanding
of the natural history of different lymphomas, but will only
be of clinical value if the sub divisions prove to have
therapeutic relevance. The curability of some NHDL and
incurability of others, have already been recognised. The
stimulus to explore new approaches to therapy will come
from the potential to influence the behaviour of newly
identified sub groups. Factors influencing treatment strategy,
and the current objectives of therapy will be reviewed.
Treatment of human lymphoma with derivatives of
anti-idiotype antibodies
G.T. Stevenson
Lymphoma Research Unit, Tenovus Laboratory, General
Hospital, Southampton S09 4XY, UK.
Lymphomas offer a wealth of differentiation antigens for
exploitation either as tumour markers or as targets for
therapeutic antibody. Preeminent antigens as regards
specificity and characterisation are the idiotypes of surface Ig
and the T-cell receptor. Therapeutic antibody can damage
the tumour by delivering to it an exogenous toxic agent, or
by recruiting the host's own cytotoxic agents such as
complement and various cellular effectors. The latter strategy
is the one that we have studied the more intensively.
We are using chimeric univalent derivatives of monoclonal
antiidiotype antibodies to treat human B-cell lymphoma. The
derivatives recruit host effectors efficiently, avoid rapid
antigenic modulation, and have a good metabolic survival.
Our current protocol provides them for intramuscular
injection, which is vastly more convenient than intravenous
infusion. Results, problems and future trends will be
discussed.
Abstracts of members' proferred papers
Growth and morphology of a cell line from Jaagsiekte, a
contagious lung tumour of sheep, can be manipulated in vitro
F.A. Jassim, J.M. Sharp, K.W. Angus & J. Menzies
Moredun Research Institute, 408 Gilmerton Road, Edinburgh
EHJ7 7JH, UK.
Jaagsiekte is a contagious lung tumour of sheep in which
two secretory epithelial cells in the lower respiratory tract are
transformed. These cells are type II pneumocytes in the
alveoli and the cells of Clara in the terminal bronchioles. A
cell line (JS7) has been established from the lungs of sheep
with jaagsiekte and has been propagated continuously in
vitro for more than 140 passages. The cells possess properties
of transformed cells such as growth in soft agar and athymic
mice, yet retain many of the characteristic differentiated
features of type II pneumocytes. The effect of bromohexineJOINT MEETING OF THE BACR, EACR AND THE RSM 335
HCI and prednisolone on the morphology and ultrastructure
of JS7 cells was studied. Cells were cultured for up to six
days in medium with various concentrations of the two
chemicals. Cells treated with prednisolone lost their
squamous epithelial shape and assumed a fusiform swirling
appearance. Coincident with this change in morphology,
they also lost the characteristic cytoplasmic lamellar bodies
but not apical microvilli nor desmosomes. Cells treated with
bromohexine HCI showed an increase in the number and
size of lamellar bodies. These data indicate that
differentiated features of this important pulmonary epithelial
cell can be manipulated in vitro.
Chemosentivity testing of human lung cancer cell lines using a
colorimetric assay
J. Carmichael, W.B. De Graff, J. Gamson, A.F. Gazdar,
J.D. Minna & J.B. Mitchell
Naval Med. Oncol. Branch, NCI and Naval Hospital,
Bethesda, Maryland, USA.
A colorimetric assay was used to determine the chemo-
sensitivity profile of 30 human lung cancer cell lines. The
assay is based on the cellular reduction of MTT, a
tetrazolium salt, to a purple coloured formazan product
which can be measured spectrophotometrically, with
production of formazan proportional to viable cell number.
Of 15 small cell lung cancer lines (SCLC) tested, 7 were
derived from previously untreated patients (Un/T). The non-
small cell lung cancer I
carcinoma, 3 large
bronchioloalveolar, 2 sqt
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A high molecular weight
peptide (GRP) growth fa
J.L. Millar, V. Macaula)
Section ofMedicine, Inst
Unit, Royal Marsden Ho
novel growth assay in which uptake of '4C-thymidine (14C),
3H-uridine (3H) and 75Selenomethionine (75Se) indicate the
rate of synthesis of DNA, RNA and protein respectively.
Label uptake is linear with time in control HC12 cells
growing in RPMI alone. Addition of FD CM stimulates
incorporation of 14C (by 500% over control at 40h), 3H
(220%), and "Se (130%); enhanced label uptake correlates
with increase in cell number. The bombesin-homologous
fragment of GRP (amino acids 14 to 27, at 5 ,ug ml-')
caused less marked stimulation of uptake of 14C (210% at
40h), 3H (108%) and 7'Se (81%). Notably, the GRP effect
on DNA synthesis was less than that reported by Weber et
al., 1985 (J. Clin. Invest., 75, 306). HC12 expresses BLI, but
bombesin/GRP receptors may be down regulated in the
presence of high MW growth factor/receptor interaction.
HC12 FD CM also stimulates label uptake in another
'classic' SCLC line; we plan targetting experiments in other
SCLC and non-SCLC lines, and hope to further characterise
this putative growth factor.
Cytotoxic drug targetting to lung cancer cells in vitro with a
complex of low density lipoprotein (LDL)-daunomycin
D.J. Kerr', S. Hynds2, T.E. Wheldon3, J. Shepherd2 & S.B.
Kaye'
'Department ofMedical Oncology and 2 Clinical
Biochemistry, University ofGlasgow; 3Radiobiology Group,
Belvidere Hospital, Glasgow, UK.
lines (NSCLC) comprised 4 adeno- High affinity LDL-receptors have been demonstrated on the
cell, 2 adenosquamous, 2 cell surface of epidermal cervical carcinoma cells, glioma and
iamous and 2 mesothelioma cell lines. P388 and human leukaemic cells in vitro. Using '251-labelled
assessed by following continuous LDL we have demonstrated high affinity saturable binding
a 4 day assay, with the ID50 defined sites for LDL (Vmax = 125cpm Pg cell protein,
;ulting in a 50% reduction in MTT Km =40 pml ')on a human non-small cell lung tumour line
Representative ID50 values are (L-DAN). A stable LDL-daunomycin complex has been
ng table: synthesised and its cytotoxicity in monolayer and spheroid,
cellular uptake and metabolism has been compared to free
Un/T SCLC T-SCLC NSCLC daunomycin. The respective monolayer clonogenic ID90s for
(n=7) (n =8) (n=15) LDL-daunomycin and free daunomycin are 1.0pgml - and
3.98 17.28 37.04 1.2pgml-'. Drug uptake studies were performed on
0.88 2.54 4.03 monolayers, following exposure to drug at fixed
26.28 167.24 205.40 concentration (5pgml-') for up to 2h. Intracellular
1.24 10.26 31.44 daunomycin and its metabolite daunomycinol were measured
using HPLC. Daunomycin was extensively metabolised to
;CLC lines were more sensitive than the relatively inactive daunomycinol, so that by 2h the
NSCLC lines least sensitive. These alcohol predominated over the parent drug. Intracellular
ng with clinical experience using daunomycin levels were similar following exposure to
ell types. This colorimetric assay can both drugs, although total intracellular drug (daunomycin
therefore offers a rapid, reproducible +daunomycinol) was 50% higher after free daunomycin,
itivity testing of cell lines. implying that LDL protects daunomycin from metabolism.
L-DAN spheroid growth delay was measured following
treatment with both free and LDL-bound daunomycin.
ctor in small cell lung cancer (SCLC) LDL-daunomycin induced significantly longer growth delay
at each concentration and appeared to increase the intra-
y, G.P. Joshi & I.E. Smith spheroidal depth to which daunomycin diffused, as assessed
by fluorescent microscopy. It is possible that the LDL-
daunomycin complex increases daunomycin penetration in situte onceres , adu spheroids and enhances cytotoxicity.
sspital, Sutton, Surrey, UK.
Autocrine growth factor secretion may explain rapid
proliferation in SCLC. Bombesin/GRP (MW 1620/2800) is
produced by and mitogenic to 'classic' SCLC cultures, but is
absent in the more rapidly growing 'variant' lines. We are
studying a 'classic' SCLC line, HC12, which proliferates in
serum-free medium, without specific supplements. HC12
conditioned medium (CM) was lyophilised, reconstituted in
aqueous solution and dialysed against 0.9% saline across
cellulose membrane (approx. MW cut-off 10-12kDa). The
final preparation (FD CM) combined no detectable
bombesin-like immunoreactivity (BLI). We have developed a
Determinants of prognosis in small cell lung cancer at
presentation and in response to chemotherapy
H. Earl', R.L. Souhami', C.M. Ash', S.G. Spiro2,
P.G. Harper3, J.S. Tobias' & D.M. Geddes4
' University College Hospital, 2Brompton Hospital, 3Guy's
Hospital, 4London Chest Hospital, UK.
Clinical and biochemical parameters in patients treated in a
randomised prospective trial of 370 patients were analysed336 JOINT MEETING OF THE BACR, EACR AND THE RSM
for their influence on prognosis, using a multiple regression
analysis. All of the prognostic information was given by
initial performance, serum sodium, albumin, alkaline
phosphatase and disease extent, all measured at presentation.
Patients in whom all the biochemical factors were normal
with performance status (Karnovsky) >70 and limited
disease, had a greater than 15% chance of surviving 2 years.
A separate analysis on a new data set of 640 patients has
confirmed these findings and has shown a quantitative
relationship between survival, performance status, and level
of alkaline phosphatase. Almost all the long survivors in this
new study had limited disease and no biochemical
abnormality at presentation.
Further analyses have shown that the effect of adverse
prognostic factors at presentation diminished with time.
Detailed analyses of sequential data indicates that if
treatment normalises adverse factors, the prognosis
improves. These data are of significant help in deciding how
long chemotherapy should continue especially in patients
with an initially poor prognosis.
Increased N-myc expression in human small cell carcinoma of
the lung indicate poor prognosis
J. Bergh1, E. N6u2 & K. Fina3
'Department ofOncology, 2Department ofLung Medicine,
3Department ofImmunology, University of Uppsala, S-751 85
Uppsala, Sweden.
Human small cell carcinoma of the lung (SCCL) is
characterized by an initial prompt response to radio- and
chemotherapy. Unfortunately, -90% of the patients relapse
within 5 years with clones of SCCL, which are resistant to
therapy. SCCL cell lines have previously been demonstrated,
in certain instances, to have amplified and increased
expression of the proto-oncogenes c- and N-myc. SCCL cell
lines with increased levels of c-myc, mostly have a more
rapid growth and also a decreased expression of some
neuroendocrine markers for SCCL vs. non-SCCL
(squamous-, adeno- and large cell carcinomas of the lung).
In this study we have examined biopsies from 15 untreated
patients with SCCL using 35-S-labelled RNA probes against
N-myc. Deparaffinized sections were used after proteinase K
and acetic anhydride- glycine treatment with a 1.7Kb
EcoRI-Bgl 11 genomic fragment of the third exon of the
human N-myc. A primary lung-adenocarcinoma biopsy was
used as positive control, while this tumour previously has
been demonstrated to contain N-myc amplification using
Southern blots. To evaluate the results of the SCCL biopsies
the number of grains was calculated. Six of 7 patients with
complete responses and a median survival time of 22 months
(range 9-64 months) were negative for N-myc expression.
The 6 patients with N-myc positive SCCL biopsies had,
together with 2 negative patients, only partial- or no
responses; with a median survival of 13 months (range 6-16
months).
Intermittent chemo/radiotherapy in small cell lung cancer:
A novel approach to combined modality therapy
M.H. Cullen, N.S. Stuart, C.M. Woodroffe, R.J. Grieve',
A.D. Chetiyawardana, T.J. Priestman, D. Spooner &
G.H. Benfield
Department of Radiotherapy and Oncology, Queen Elizabeth
Hospital, Birmingham, 1Department ofRadiotherapy,
Coventry and Warwickshire Hospital, UK.
The role of thoracic radiotherapy (TRT) in small cell cancer
is controversial even in limited disease (LD). Concurrent
chemotherapy (CT) and TRT may confer benefit, but at the
expense of substantial local toxicity. In this study TRT is
used as a localized cytotoxic agent given intermittently the
day following i.v. CT.
Forty-eight patients are currently on study. Eleven patients
received VACR (dl: vincristine 1 mgm-2, adriamycin
40mgm-2, cyclophosphamide 1000mgm-2i.v.; d2: TRT 400
cGY-q2ld x 6). Thirty-seven patients received RAVE (dl:
vincristine 1 mgm-2, adriamycin 40mgm-2, etoposide
120 mgm-2 i.v.; d2: etoposide 250mgm-2 po, TRT 400 cGy
(17 patients), 500 cGy (20 patients)-q21d x 6). Thirty-six
patients have LD, 12 extensive disease (ED). Forty-seven are
evaluable for response:
Eval.for
Stage response CR (X-ray) CRb- CRb+ CRbo PR F
LD 35 23 9 2 12 8 4
ED 12 7 4 1 2 1 4
b- =bronchoscopy negative; b+ =bronchoscopy positive; bo-
bronchoscopy refused.
Of 30 CR patients, 22 have relapsed. Only 6 of these have
occurred within the TRT field. Sixteen have occurred at
distant sites with no local failure. Three of these were in the
CNS.
The median survival of LD patients is 65.5 weeks and 29
weeks for ED. Four patients are alive and disease free at
95+-171+ weeks.
The toxicity of concurrent therapy has been minimal. Two
patients have had symptomatic oesophagitis, both transient.
Radiation pulmonary fibrosis was present on X-ray at 6
months in 11/14 evaluable patients having 6 x 500cGy
fractions, but no other late effects of RT have occurred.
Intermittent chemo/radiotherapy may induce high response
rates in the chest with little symptomatic local toxicity and
few in-field recurrences.
In vitro cross-resistance patterns of anthracyclines in human
non-small cell lung cancer cell lines with differing inherent
resistance to adriamycin
S. Merry, E.R. Courtney, C. McCormick, S.B. Kaye
& R.I. Freshney
CRC Department ofMedical Oncology, University of
Glasgow, Glasgow, UK.
In order to assess the potential lack of cross-resistance with
adriamycin (ADR) of 5 novel anthracycline analogues,
studies have been performed with 2 human non-small cell
lung cancer cell lines (A549 and SK-MES-1) of differing
inherent sensitivity to ADR. The 5 compounds are
idarubicin (IDA), 4'-deoxy-4'-iododoxorubicin (JODO) both
supplied by Farmitalia; a 9-methyl derivative (Ro3l/1215)
supplied by Roche; a cyanomorpholino derivative (MRA-
CN) supplied by SRI International, and a 7-hydroxyanthra-
pyrazole (CI941) supplied by Warner Lambert. Cells of the 2
cell lines were seeded onto microtitre plates and, after 96h,
were exposed to drug for a further 72h (with drug
replacement at 24 and 48 h) followed by a recovery period of
120h. Viability at the end of the assay was assessed as
tritiated leucine incorporation. Results expressed as ID50
values ( x 10 -9 M) were:
A549 SK-MES-1 RATIO
ADR 210 18 12
IDA 0.26 7.3 0.036
JODO 0.038 6.0 0.0063
Ro-31/1215 0.89 13 0.0068
MRA-CN 0.18 0.077 2.3
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These results suggest a relative lack of cross-resistance for all
these compounds except C1941, and (in our model) JODO
and Ro3l/1215 look most promising in this respect.
Cyclosporins overcome multi-drug resistance in human lung
cancer and mouse tumour cell lines
P.R. Twentyman, N.E. Fox & D.J.G. White'
MRC Clinical Oncology and Radiotherapeutics Unit and
' University ofCambridge, Department ofSurgery, Hills Road,
Cambridge, UK.
We have developed multi-drug resistant variants of the NCI-
H69 human small cell lung cancer and the EMT6 mouse
tumour cell lines. These variants show high degrees of
resistance to adriamycin (ADM), vincristine (VCR) and
colchicine. Many different chemical compounds are currently
being studied with regard to their ability to remove this
resistance. Growth inhibition during continuous drug
exposure is used as the cytotoxic drug response endpoint and
resistance factor (RF) is the ratio of drug doses to produce
50% inhibition in the resistant and parent lines.
Both parent cell lines were more sensitive to the immuno-
suppressive drug cyclosporin A (CYA) than were their
multidrug resistant variants. For ADM, the RF for the
variant lung cancer line is around 100. CYA (5ygml-1)
made little difference to the ADM sensitivity of the parent
line but considerably sensitised the resistant line, thereby
reducing the RF to around 3. The magnitude of the effect
was reduced with reducing dose of CYA, but some
sensitisation was still observed at 0.5jigml-1. Similarly the
RF for VCR could be reduced from 1,000 to 10 by 5jgml-1
of CYA. This resulted from a 300-fold sensitisation of the
resistant line compared with a 3-fold sensitisation of the
parent line. Cyclosporin C and cyclosporin G, analogues
possessing immunosuppressive properties, each showed
similar activity to CYA at a dose of 5jigml-1. The
biologically inert analogue cyclosporin H, however, had little
or no activity at 10jigml - 1. Qualitatively similar results
were obtained using the drug resistant variant of the EMT6
cell line.
These studies suggest that cyclosporins, at clinically
achievable doses, may have a role as specific sensitisers of
chemotherapy-resistant tumours.
The radiation responses of human lung tumour lines of
different histological types
G. Duchesne, J. Peacock & G. Steel
Institute ofCancer Research, Sutton, Surrey SM2 5PX, UK.
The acute in vitro responses to radiation of a panel of
human lung carcinoma lines, representing 3 of the common
histological types, were determined using a soft agar
clonogenic assay. (A squamous carcinoma failed to clone
using this technique). The survival data were analysed
according to the multitarget and linear quadratic models,
and the surviving fraction at 2Gy (SF2). The mean Do of
the classical small cell carcinomas (1.26+0.11) was
significantly lower than that of the other cell types
(1.63 +0.09, P<0.01). Significant differences in a,
representing the initial slope of the cell survival curve, were
also found between the lines: the mean oc of the lines with a
large cell component (0.19+0.03) was lower than that of the
small cell lines (0.57+0.06, P<0.01) and the
adenocarcinomas (0.38 +0.06, P<0.05), suggesting lower
intrinsic sensitivity in the large cell lines. This was confirmed
by comparison of SF2: large-cell 0.70+0.05, small-cell
0.34+0.03, P<0.01, adenocarcinoma 0.43+0.13, P=0.05.
No differences in repair of sublethal or potentially lethal
damage were observed. The results suggest that the clinical
observations of resistance in large cell tumours is due to
intrinsic cellular resistance. Improved therapeutic ratios may
be obtained by the use of hyperfractionation in the
management of small cell carcinomas and adenocarcinomas.
Control of growth on non-small cell lung cancer by
dexamethasone
J. McLean & R.I. Freshney
Department ofMedical Oncology, University ofGlasgow, I
Horselethill Road, Glasgow G12 9LX, UK.
In vitro experiments have shown that glucocorticoids are
cytostatic for glioma and both small cell and non-small cell
lung carcinoma cells. The effect is most pronounced in late
log and plateau phase cultures implying cell-cell contact may
be important. Cell surface modifications are also induced by
dexamethasone (DX) and methyl prednisolone inducing a
reduction in hyaluronic acid released into the medium
correlating with cytostasis and, possibly, enhanced cell
adhesion. DX also reduces plasminogen activator -Xtivity
and the release of mitogenic factors for endothellhim by
tumour cells in vitro, while enhancing surfactant production
in A549 alveolar carcinoma cells. This implies a shift
towards a less malignant phenotype. In vivo studies have
shown reduction in tumour growth in xenografts in nude
mice with increased central necrosis possibly due to
inhibition of angiogenesis. Treatment of NCI-H125 which
did not give a typical cytostatic or phenotypic response in
vitro, gave no inhibition of growth in xenografts implying a
cellular rather than systemic effect of the steroid.
DNA ploidy in pulminary carcinoid tumours
D.J. Jones', P.S. Hasleton2 & M. Moore'
'Paterson Institutefor Cancer Research, Christie Hospital &
Holt Radium Institute, Manchester and 2Department of
Pathology, Wythenshawe Hospital, Manchester, UK.
Carcinoid tumours account for less than 10% of broncho-
pulmonary neoplasms. They exhibit a spectrum of
histological features and clinical behaviour, varying from
histologically typical endobronchial tumours to malignant
metastasizing neuroendocrine carcinomas. DNA ploidy was
assessed by flow cytometry on paraffin embedded material
obtained from 53 patients presenting between 1961 and 1985,
according to the method of Hedley et al., J. Histochem.
Cytochem. 31, 1333, 1983), using a Coulter EPICS flow
cytometer. DNA ploidy was correlated with the following
conventional pathological features (a) type - typical/atypical,
(b) growth pattern - insular/trabecular/glandular/undifferen-
tiated, (c) vascular invasion (d) lymphatic invasion, (e)
nuclear pleomorphism (f) necrosis (g) lymph node
involvement. Statistical analysis was by Chi squared test.
26/53 were DNA aneuploid. DNA aneuploidy rates for
pathological subgroups were as follows: 9/28 typical, 17/25
atypical (P<0.02); 11/32 insular, trabecular and glandular
combined; 15/21 undifferentiated (P<0.02); 21/26 with, 5/27
without nuclear pleomorphism (P<0.001); 13/18 with, 13/35
without necrosis (P<0.05); 11/13 involved lymph nodes;
12/36 uninvolved lymph nodes (P<0.01). There was no
significant correlation between DNA aneuploidy and
vascular or lymphatic invasion. In conclusion, DNA
aneuploidy is a feature of pulmonary carcinoid tumours and
is associated with other pathological features of increasing
malignancy. DNA ploidy status is not helpful in
discriminating carcinoids from other lung tumours as
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previously suggested (Blondal et al., Eur. J. Respir, Dis., 64,
298, 1983). The presence of a detectable aneuploid
population is not a prerequisite for malignant behaviour and
aneuploidy does not invariably confer a malignant
phenotype. Subchromosomal structural changes and altered
gene expression are probably as important as gross
numerical aberrations.
Measurement of intracellular carbamoylating activity of
chloroethylnitrosoureas in intact human small cell carcinoma
(NCI-H69) and murine mammary tumour (EMT6) cells using
flow cytoenzymology
C. Dive, P. Workman & J. Watson
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge, UK.
As well as yielding DNA-interacting alkylating fragments,
chloroethylnitrosoureas decompose under physiological
conditions to generate isocyanates which carbamoylate
intracellular proteins. Carbamoylation has been implicated in
the inhibition of DNA repair and RNA processing,
enhancc.ment of radiation cytotoxicity, and degree of myelo-
suppression. We have developed a novel method of
measuring protein carbamoylation based on flow cyto-
enzymology. The major advantage over previous techniques
is that the reaction is measured in intact cells, so that
membrane penetration is considered as well as biochemical
reactivity. The assay measures inhibition of esterases using
the substrate fluorescein diacetate, which on conversion to
fluorescein accumulates in the cell reflecting enzyme activity.
Cells were preincubated with drug for 1 hr before addition of
substrate. Fluorescence was measured with time using the
Cambridge flow cytometer, cell population progress curves
constructed and the concentration of drug required to
produce 50% inhibition (I50) was calculated for a wide range
of structural analogues. Results for the human and murine
cells were very similar, and the drugs could be classified into
high, intermediate and low inhibitory potency. BCNU,
ACNU and chlorozotocin are examples of each category,
with 150 values of 7 x 10 4M, Ix 10 2M and >> 10 2 M
respectively. Though broadly in agreement with results of
previous methods, important differences were identified, e.g.
GANU exhibited weak activity in this assay, partly due to
poor membrane permeability. This assay can now be used to
study the cellular pharmacology of novel chloroethyl-
nitrosoureas under development.
Immunohistochemical staining patterns of small cell cancer of
the lung (SCCL) - Relationship to prognosis
S.G. Allan, F.G. Hay & R.C.F. Leonard
Imperial Cancer Research Fund Medical Oncology Unit,
University Department ofClinical Oncology, Western General
Hospital, Edinburgh, EH4 2XU, UK.
SCCL remains a highly lethal disease despite good response
rates achieved by chemotherapy. Potentially the linking of
clinical events to cellular behaviour could provide insight
into tumour response and prognosis. Using a panel of
monoclonal antibodies (MoAbs) we have examined tumour
cell antigen expression in a series of 38 tissue sections from
patients with SCCL in whom clinical information was
available. Thirty-eight paraffin-embedded blocks fixed in
10% buffered formalin (31 primary lesions, 7 metastatic)
were cut as 5,um sections. After dewaxing and rehydration,
endogenous peroxidase activity was blocked and sections
were trypsinised prior to incubation with MoAbs. HMFG1,
HMFG2 and CAM 5.2 were used as undiluted supernatants.
Anti-leu 7, B5, bombesin, EFG-RF4, Mo2, 534F8 and
c-myc were used at optimal dilutions. Thereafter a standard
3 step PAP technique was applied and the end product
developed using DAB/H202 with haematoxylin counter
staining. In the 31 primary lesions positive staining (10% or
more) was achieved in 17/31 HMFG2, 10/15 HFMG1,
27/29B5, 15/31 534F8, 2/31 EGF/RF4, 5/18 Mo2, Leu-7
3/28, bombesin 0/18, c-myc 0/22. A positive inverse
relationship with survival was demonstrated for HMFG2
staining - mean 8.1 mo for HMFG2 positive vs. 15.2mo for
HMFG2 negative (p<0.05, Mann-Whitney). No relation-
ship to survival was shown for other antibodies. In the few
samples expressing F4 positivity survival was very short.
Further studies of HMFG2 and its use as a marker in SCCL
are indicated.
Oral ifosfamide and etoposide for small cell lung cancer
patients
M. Lind', N. Thatcher1, T. Cerny' & K. Carroll2
ICRC Department of Medical Oncology, Christie Hospital &
Holt Radium Institute and 2 Wythenshawe Hospital,
Manchester, UK.
In elderly and poor prognosis patients with small cell lung
cancer simple treatments with rapid responses and rapid
improvement of symptoms with low toxicity are desirable.
The response rate for i.v. ifosfamide and etoposide is 63%
for extensive disease and 90% for limited disease. The
bioavailability for oral ifosfamide is 100%.
We have treated 45 patients with SCLC with ifosfamide
(2g p.o. days 1-3 with equidose mesna) and oral etoposide
100mg days 1-8 repeated every 3-4 weeks for a maximum of
6 courses.
There were 15CRs and 22PRs giving an overall response
rate of 92%. There was only 1 treatment related death
(septicaemia). There were no cases of cystitis and the
incidence of severe encephalopathy 8%.
Small cell lung cancer: A phase 2 evaluation of
r-interferon-y(immuneron) in 12 previously untreated patients
H. Newman & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge, UK.
Although up to 80% of patients with small cell lung cancer
will respond to chemotherapy initially, survival at 2 years is
only 15%. Alpha interferons have not proved effective in
this disease, and have shown significant toxicity (Jones D.H.
et al., Br. J. Cancer, 47, 361, 1983). Gamma interferons
differ from the x-molecule, notably possessing greater
cytotoxic and immunomodulatory activity. Immuneron (r-
IFN-y) has been shown to inhibit the growth of small cell
lines in vitro (Twentyman, P.R. et al., Br. J. Cancer, 52, 21,
1985). This agent was therefore assessed under optimal
conditions in previously untreated patients. A dose of
1 mgm-2 day-1 for 5 days continuously was followed by a
maintenance dose of 0.5mgm 2 thrice weekly, being given
i.v. over 30min. The trial was stopped after 12 of the 14
projected patients had been treated, because of poor
responses. Four patients are considered non-evaluable for
response; one was withdrawn because of hypotension, one
developed spinal cord compression, and two died from
intercurrent illness not thought to be Immuneron related. Of
the remaining 8 patients 4 had stable disease for 1 month,
and 4 had progressive disease within 3 weeks on therapy.
Toxicity consisted mainly of pyrexia (11/12) and malaise
(10/12). The lowest total WBC was 2.0, and transient rise inJOINT MEETING OF THE BACR, EACR AND THE RSM 339
SGPT at the end of week 1 was seen in 9/12 patients. Paired
serum for E. coli and r-IFN-y antibodies were taken and
results will be presented. Ten patients subsequently received
chemotherapy; there were 7 responses, 3 being complete. The
mean duration of response was 8 months. It is concluded
that Immuneron has no clinically significant single agent
activity in small cell lung cancer.
Neuron specific enolase and CEA compared in small cell lung
cancer
E.H. Cooper', L. J0rgensen2, H. Hansen2 & M.D. Peake3
1 Unitfor Cancer Research, University ofLeeds, Leeds LS2
9NL; 2Finsen Institute, 2100 Copenhagen and 3 Pontefract
General Infirmary, Pontefract WF8 IPL, UK.
The serum levels of neuron specific enolase (NSE) and
carcinoembryonic antigen (CEA) were measured in 98
patients with SCLC before treatment. In patients with
limited disease 37/57 (64%) had a raised NSE > 12.5ngml-I
and 19/57 (33%) had a CEA >6ngml-1, in 29/57 (51%),
the CEA was >3ngml-i. In extensive disease 33/41 (80%)
had a raised NSE, and 18/41 (44%) a CEA >3ngml-1. The
combination of an NSE > 12.5ngml- and/or CEA
>6ngml-' occurred in 70/98 (71%) patients at
presentation. Levels of NSE >25ngml- ' are highly
suspicious of SCLC but at this level the test would only
detect 46% of the patients in our series. With the exception
of 5 non-responders, chemotherapy was associated with the
NSE falling rapidly to reach 4-1Ongml-l after one or two
courses. Partial and complete responses could not be
distinguished by their NSE plateau levels. In 26 incidences of
systemic progressive disease a rising NSE was observed in 23
(88%) of these incidences; a rising CEA was observed in
40%. Isolated metastases in the central nervous system did
not produce a rise of NSE. Serum NSE can provide a
monitor for patients with SCLC receiving chemotherapy,
and provides evidence of progression during chemotherapy
or after treatment has been completed.
Antibody-guided targetting of non-small lung cancer using
radiolabelled HMFG1 (Fab')2 fragments
H. Kalofonos, N. Courtney-Luck, J.P. Lavender,
G. Hooker, G. Robinson, D. Snook, J. Taylor-
Papadimitrioul & A.A. Epenetos
Royal Postgraduate Medical School, Ducane Road, London,
W12 OHS and Imperial Cancer Research Fund, Lincoln's Inn
Fields, London, WC2 3PX, UK.
(Fab')2 fragments of tumour associated monoclonal
antibody HMFG1 were prepared and radiolabelled with
indium 111-In. Radiolabelled antibody was shown to be
stable both in vitro and in vivo and there was no significant
loss of immunoreactivity. Ten patients with non-small
primary and metastatic lung cancer (NSCC) were studied by
radio-immunoscintigraphy after i.v. administration of 1I -In
labelled (Fab')2 HMFG1. Successful localisation was
observed in all patients with no significant uptake in any
normal tissue, except for liver (accumulating - 20% of
injected amount). A new radiolabelled 90 Yttrium has been
chelated to HMFG1 (Fab')2 fragments for potential
antibody guided therapy of lung cancer. Following the
procedure, there was no loss of antibody immunoreactivity.
The radiolabelled antibody was found to be stable both in
vitro and in vivo as studied in pre-clinical trials. We conclude
that 111-In labelled HMFG1 (Fab')2 fragments are an
important new development in the radio-immunolocalisation
of NSCC lung cancer and that 90-Y labelled antibody is
potentially suitable for therapeutic use.
Tumour marker measurements in spermatic vein blood of
testicular cancer patients
P.A. Light', & C.J. Tyrrell2
'Radiotherapy and Oncology Centre, Bristol BS2 8ED and
2Department ofRadiotherapy, Plymouth General Hospital,
Plymouth PL4 7JJ, UK.
Alphafoetoprotein (AFP) and/or chorionic gonadotrophin
(hCG) are present in the blood of many patients with
testicular cancer, and the estimation of these markers pre-
and post-operatively is now of established value in the
management of this group of patients. A recent study of
marker concentrations in spermatic vein blood (s.v.b., taken
at the time of orchidectomy) has shown that these
measurements may be of particular value in patients whose
tumours produce only small amounts of marker(s), such
that, although measurable in s.v.b. draining directly from the
tumour, they fall below the level of detection after dilution
in the peripheral circulation. Further studies have shown
that the ratio of marker concentration between s.v.b. and
peripheral blood (p.b.) may vary greatly between patients.
The biggest differences were seen in patients in whom disease
was subsequently found to be Stage 1 (i.e. disease confined
to the testis), and in this group s.v.b. marker values were
higher or very much higher than p.b. values. However, in
patients who were subsequently found to have widespread or
bulky metastatic disease, the s.v.b. marker values were only
slightly greater than p.b. values or, in some cases, not
significantly different. Assessment of such marker
concentration ratios may assist in the early identification of
metastatic disease.
Expression of the c-myc oncogene product in gastric cancer
and associated 'pre-malignant' lesions
F. Macdonald, W.H. Allum, H. Stokes & B. Russell
Surgical Immunology Unit, Queen Elizabeth Hospital,
Edgbaston, Birmingham, UK.
Clearly defined pre-malignant changes have not been
identified in gastric cancer. However, both atrophic gastritis
and intestinal metaplasia have been found in association
with cancers. Dysplastic lesions have also been studied to
determine their involvement with this disease. In an attempt
to identify a marker which may indicate those conditions
likely to develop into frank malignancy, we have examined
the role played by oncogenes in the development of this
disease. Tissues from patients with inflammatory, 'pre-
malignant' and malignant conditions of the stomach as well
as normals have been examined in an immunohistochemical
test with an antibody to the c-myc oncogene protein.
Biopsies from 130 patients entered into a trial for the
detection of early gastric cancer were examined. Strong
expression of the c-myc protein was detected in 54% of
patients with intestinal metaplasia, 66% of those with
atrophic gastritis and 60% of those with dysplasia compared
with only 10% of patients with superficial gastritis. Intense
staining was seen in 7/10 patients who had atrophic gastritis
in association with incomplete intestinal metaplasia - a
condition linked with 'intestinal' cancers of the stomach.
Staining in the 96 cancers tested was less intense but was
found in 42% of those belonging to the 'intestinal' group
compared with 23% of the 'diffuse' group. A similar pattern
was observed in autologous lymph node metastases.
Sequential biopsies obtained from two patients who340 JOINT MEETING OF THE BACR, EACR AND THE RSM
developed early gastric cancer, following an initial diagnosis
of intestinal metaplasia/atrophic gastritis, showed strong
expression of c-myc in early biopsies. These results suggest
that c-myc may be a useful marker to identify those lesions
which will develop into frank malignancy.
Radiotherapy employing three fractions each day over a
continuous period of 12 days
M.I. Saunders & S. Dische
Marie Curie Research Wing, Regional Radiotherapy and
Oncology Centre, Mount Vernon Hospital, Northwood,
Middlesex HA6 2RN, UK.
Biological evidence suggests that in the radiotherapy of
human tumours regrowth between fractions is much more
important as a cause for failure to control than was
considered formerly. Accelerated fractionation using multiple
treatments in one day should lead to a reduction in time for
regrowth between fractions. Most workers who have used
accelerated fractionation have not been able to complete
treatment to a satisfactory total dose without introducing a
split-course schedule. It follows, however, that with
accelerated fractionation a pause in treatment during a rest
period and/or during a week-end is likely to negate the
benefit that may be obtained.
In order to avoid such interruptions a scheme of
radiotherapy has been planned which gives a total tumour
dose of 50.4Gy in 36 fractions given three times a day over
12 consecutive days. In a pilot study of 39 patients 23 have
shown advanced bronchial carcinoma. The predicted acute
reactions in the oesophagus have not been excessive and no
other immediate problems have developed. So far late
changes appear no greater, and perhaps are less evident,
than with conventional treatment, but the follow up time
remains short. Immediate tumour responses are very
promising, complete regression being observed in 40% to be
compared with 14% in a previous comparable series. The
good tolerance has now allowed an increase in the total dose
to 54Gy.
Psychosocial sequelae of mastectomy v. breast conservation
L.J. Fallowfield', M. Baum' & G.P. Maguire2
1CRC Trials Centre, Department ofSurgery, King's College
Hospital, London SE5 and 2Department ofPsychiatry,
University Hospital ofS. Manchester, Manchester M20 8LR,
UK.
High levels of psychiatric morbidity are well-known sequelae
of a diagnosis of breast cancer and its treatment by
mastectomy. This, together with survival data accumulating
from studies comparing mastectomy with more conservative
surgery, has led many surgeons to offer breast conservation
as primary treatment. There is to date no satisfactory
empirical evidence supporting the intuitive assumption that
local excision and radiotherapy protects women from the
anxiety and depression experienced by patients who undergo
mastectomy. The CRC's Breast Conservation Trial provided
a unique opportunity to examine this issue. We present
psychological data from 101 women randomised to either
lumpectomy or mastectomy. The levels of psychiatric
morbidity as measured by a semi-structured interview and 2
self-report questionnaires were similar in both treatment
groups. Approximately 15 months post-operatively, 21% of
the mastectomy patients were depressed and 26% were
anxious. Amongst the lumpectomy patients 27% were
depressed and 31% experiencing anxiety. Furthermore, over
one third of patients in both groups reported a lack of
sexual interest. These unexpected results are discussed,
together with their implications for clinical practice and
counselling services.
Oral CGP 32349 (4-hydroxyandrostenedione) has antitumour
activity in breast cancer
D. Cunningham', T.J. Powles2, M. Dowsett3, H.T. Ford',
J.-C. Gazet', G. Hutchison', A.M. Brodie4 &
R.C. Coombes' 2,5
'St. George's Hospital, London SW17; 2Royal Marsden
Hospital, Surrey; 3Chelsea Hospitalfor Women, London
SW3; 4University ofMaryland School ofMedicine, Baltimore
USA and 5Ludwig Institutefor Cancer Research (London
Branch) St. George's Hospital Medical School, London SWi7,
UK.
We have previously shown that 4-hydroxyandrostenedione
(4-OHA), a potent aromatase inhibitor has significant
antitumour activity when administered parenterally to post-
menopausal women with breast cancer. This is the first
report of the use of 4-OHA administered orally.
Thirty-one female patients, mean age 65.7yrs (range 40-82
yrs) with locally advanced or inoperable breast cancer were
treated with 4-OHA given orally at a dose of 500mg daily.
All were postmenopausal. Seventeen (54%) had been given
previous endocrine therapy with 1 agent, 6 (19%) had
received 2 agents and 3 (10%) had received 3 agents with an
overall response rate of 60%. Response to 4-OHA was as
follows. Eight (26%) had a partial response (PR) with a
median duration > 10 months; 6 remain in remission. Four
(13%) patients had stable disease (SD), 11 (36%) had
progressive disease (PD) and 8 (25%) were not evaluable.
Ten patients had ER positive tumours and 5 (50%)
responded (PR+SD). One of 9 patients with ER negative
tumours responded and 6 (50%) of 12 patients with ER
unknown tumours responded (PR+SD). In 16 of the 31
patients serial plasma oestradiols were measured and were
lowered to 53+8% of baseline levels within 7 days of
commencing 4-OHA. Thirty patients were evaluable for
toxicity. Twenty-seven (90%) experienced no side effects; a
patient had an erythematous skin rash and 1 patient had
facial swelling. In 1 patient treatment was discontinued due
to leucopaenia (WBC=2.5).
Oral 4-OHA is a new treatment for post menopausal
women with breast cancer which has few side effects.
Repeat bone marrow aspirates in patients with primary breast
cancer
J.L. Mansi, U. Berger, T. McDonnell & R.C. Coombes
Ludwig Institutefor Cancer Research (London Branch),
St. George's Hospital, London SWl7 ORE, UK.
A major problem in preventing relapse in breast cancer
patients is selecting the appropriate adjuvant therapy and
knowing for how long to treat. In order to try and address
this problem we have sampled marrow for micrometastases
before and after adjuvant therapy. Tumour cells were found
in the bone marrow of 26.4% (81/307) of patients with
primary breast cancer when multiple aspirates are taken at
the time of initial surgery and stained with an antiserum to
epithelial membrane antigen (EMA). We have now repeated
multiple aspirates in 75 patients at a mean time of 15
months after surgery. In 36 patients who had not received
adjuvant therapy, 15 had micrometastases initially and 9
remained positive, and of 21 that were negative for tumour
cells initially 17 remained negative. In contrast, of the 39
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became negative and 7/27 (26%) who were initially negative
became positive during therapy. These results indicate that,
whilst a minority of patients who do not receive adjuvant
therapy become negative for micrometastases, 75% of
patients who receive treatment become negative indicating
possible effectiveness of therapy. We now intend to repeat
the study in these patients at annual intervals to determine
how long they eradicate micrometastases.
High dose BCNU primary chemotherapy with full dose
radiotherapy for astrocytoma grade IV
E. Mbidde, P. Selby, P. Workman, A. Whitton,
T.J. McElwain & H.J.G. Bloom
Departments ofMedicine and Radiotherapy, Royal Marsden
Hospital, Sutton and MRC Clinical Oncology and
Radiotherapeutics Unit, Cambridge, UK.
We are evaluating the use of high dose BCNU (800mg-
1 gm-2) with autologous bone marrow grafting as the first
post-surgical treatment of patients with astrocytoma grade
IV. It is followed by full dose radiotherapy. Detailed
pharmacokinetic studies using reverse phrase HPLC indicate
that peak plasma concentrations range from 8.5-15.9pgml-1
in the 5 patients studied. Rapid biphasic elimination occurs
in the first 12h, with concentrations at that time ranging
from 0.03-0.056jugml-1 with some evidence of a third
phase. Returning the bone marrow graft at 24-30h allowed
successful reconstitution.
Seventeen patients have been treated on this programme.
Median follow up 1 year (range 3-27 months). Nine patients
remain alive, with 2 year actuarial probability of survival of
55%, comparing favourably with historical experience.
Leucopenia and thrombocytopaenia were of short duration,
but there were 3 cases of pneumonitis, 2 of which were fatal,
and 1 fatal hepatic toxicity. This approach to high grade
glioma deserves further evaluation in a controlled trial.
Is high dose melphalan (HDM) of value in treatment of
advanced neuroblastoma (AN)? Preliminary results of a
randomized trial by the European Neuroblastoma Study Group
(ENSG)
J. Pritchard', S. Germond', D. Jones2, J. de Kraker4
& S. Love3
'Hospitalfor Sick Children, London WCJN 3JH;
2St. George's Hospital Medical School; 3ICRF, London and
4Emmakinderziekenhaus, Amsterdamfor the ENSG.
The value of high dose consolidation chemotherapy has not
been tested by randomized study in any paediatric solid
tumour. In 1/82, the ENSG started a randomized Trial to
test the value of HDM in children with AN. Up to 3/85, 140
patients (pts) over 6 mo. of age with 'Evans' stage 3 or 4
disease, consecutively referred to 18 centres, were given 3-4
weekly OPEC induction therapy - day (d) 1: vincristine
1.5mgm-2, cyclophosphamide 600mgm 2, d2: cisplatin
60mgm 2. d4: VM26 150 mgm2. Surgical removal of
primary tumour was carried out before or during OPEC.
There was no radiotherapy. Ninety-five pts (68) achieved
complete (CR=disappearance of all evidence of tumour) or
good partial response (GPR=disappearance of all evidence
of secondary deposits and shrinkage of primary by >50% in
3 dimensions) and were eligible for randomization after
stratification for stage and centre. Because of non-
compliance by some parents and physicians only 65 pts were
randomized, 32 to HDM (180mgm-2) with autologous bone
marrow rescue) and 33 to no further treatment (NFT). There
were 2 HDM-related deaths from sepsis/neutropenia but life-
table analysis at 9/85 showed that pts in the HDM group
had better disease-free survival (P=0.03 logrank) and
survival (P=0.03) than those in the NFT group. Though
more follow-up is needed to ascertain eventual outcome we
conclude that HDM/ABM is of benefit to children with AN
who have responded to OPEC and surgery.
Cardiotoxicity of mitozantrone assessed by stress and resting
nuclear ventriculography
J. Cassidy', M.V. Merrick2, J.F. Smyth' & R.C.F. Leonard'
' University Department ofClinical Oncology and 2Department
ofNuclear Medicine, Western General Hospital, Edinburgh
EH4 2XU, UK.
Twenty-eight patients with advanced breast cancer who had
not previously received cytotoxic therapy or mediastinal
radiotherapy were randomised to treatment with
combination chemotherapy using vincristine 1.4mgm 2,
doxorubicin 50mgm-2 and prednisolone 40mg orally days
1-5 (VAP), or vincristine 1.4mgm 2, mitozantrone
14mgm 2, prednisolone 40mg orally days 1-5 (VMP) every
21 days. Before, during and after cessation of treatment
radionuclide assessment of ventricular performance was
obtained at rest, in response to cold pressor stress and on
recovery from stress. Six of 14 patients (43%) in the VAP
group, and 6 of 14 patients (43%) in the VMP group
developed abnormalities of left ventricular ejection fraction.
One patient receiving VMP developed congestive cardiac
failure. Mitozantrone is an active agent in the treatment of
advanced breast cancer but can produce cardiotoxicity. In
this middle-aged population with no other risk factors the
instance was similar to that seen with doxorubicin. Cardio-
toxicity occurred over a wide range of cumulative doses (25-
112 mgm-2). Further investigation is required to determine
the nature and prognosis of this condition.
Long-term side-effects of chemotherapy for testicular cancer
N.S.A. Stuart, C.M. Woodroffe, R. Grundy & M.H. Cullen
Queen Elizabeth Hospital, Birmingham, B15 2TL, U.K.
Recent advances in chemotherapy (CT) have led to the
prospect of cure for the majority of men with advanced
testicular cancer. We have studied the long-term physical
side-effects of such treatments. Thirty-six patients (pts) who
had been treated with CT for testicular cancer in the period
1979-1983 and who remained disease-free were asked to take
part in the study; 24 agreed to do so. Mean age of study pts
was 33 (range 20-51), median time since start of CT was 33
months (6-63). All pts had received cis-platinum (CPt),
bleomycin (B) and vinblastine (V). Mean doses given (range)
were CPt 647mg (300-1190), B 320mg (135-675), V 75mg
(40-160). Four pts had also received etoposide and 3 pts
actinomycin-D. Median number of courses of CT given was
3.5.
Renalfunction: Prior to CT all pts had normal serum urea
and creatinine. After CT 2 had raised urea and 3 raised
creatinine. Creatinine after CT showed a strong correlation
with total dose of CPt. There was no correlation with age or
time since treatment. Endocrine junction: All pts had
normal serum testosterone and free-T4. 11/21 (52%) had
raised TSH, 16/24 (67%) had raised LH and 18/24 (75%)
had raised FSH. Endocrine dysfunction was more severe in
older patients. Audiometry: Prior to CT 5 pts had
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hearing loss. The majority of pts had objective high-tone
hearing loss with 50% having <20db mean hearing loss for
both ears at 6-8 khz. Seven pts (29%) had subjective hearing
loss. Extent of high-tone hearing loss was strongly correlated
with total dose of CPt but not with age. Semenalysis: 4pts
had no semenalysis. All pts not azoospermic on first testing
were asked to have repeat semenalysis; 13 agreed. Thus 33
semenalyses were done in 20pts. Total dose of CPt and V
were strongly correlated with reduced sperm counts (SC),
reduced motility and reduced % of motile sperm. There were
no correlations with age. Pulmonary Function: Peak flow rate
and CO transfer factor were below predicted for height, age
and ethnic origin in more patients than would be expected
by chance although only in one pt was CO transfer factor
reduced below 2 standard deviations of predicted and there
was no correlation with dose of bleomycin. Inspiratory
capacity, vital capacity and effective alveolar volume were
within the predicted range in all pts but each showed
significant inverse correlations with total dose of bleomycin.
CT for testicular cancer causes long-term disturbance of
renal, endocrine, pulmonary, audiometric, and reproductive
function which is largely dose-related. Except for hearing
loss this disturbance is asymptomatic but further follow-up is
required to determine whether these abnormalities have any
future significance.
Altered size distribution of Ha-ras restriction fragments in
patients with colorectal cancer
D. Wynford-Thomas, F.S. Wyllie, N.R. Lemoine,
G.T. Williams, E.D. Williams & V. Wynford-Thomas
Cancer Biology Unit, Department ofPathology, University of
Wales College ofMedicine, Cardiff, UK.
The human Ha-ras oncogene locus demonstrates a Bam H1
restriction fragment length polymorphism (RFLP) due to
variation in copy number of a 28bp 3' tandem repeat.
Studies of patients with a variety of tumours have suggested
an association of certain rare alleles with susceptibility to
cancer. We have analysed leucocyte DNA from 15 patients
with a single histological tumour type - adenocarcinoma of
the colon/rectum - and from 13 controls with no family
history of cancer. Southern blots of Bam H1 digested DNA
were hybridised with a 32P labelled 6.6kbp genomic Ha-ras
probe. Restriction fragment sizes were estimated by reference
to a Hind III i digest and to 2 internal standards (95%
confidence limits: +0.15 kbp). Leucocyte DNA in both
patients and controls showed the expected RFLP with a
predominant (6.6kbp) and a variety of less frequent (6.1-
8.4kbp) alleles. While there was little difference in the
overall range of sizes there was a major change in the shape
of the distribution. The frequency of the predominant
6.6kbp allele was reduced from 19 out of 26 (73%) in
controls to 9 out of 30 (30%) in cancer patients (X2 =8.7;
P<0.01), with a corresponding 'flattening' of the
distribution. (No estimate of 'rare' allele frequencies was
attempted.) While our control data agrees with previous
reports, our data on colorectal cancer patients contrasts with
previous analyses of myelodysplasia and a mixed tumour
series, which showed no significant decrease in the frequency
of the predominant allele in leucocyte DNA. We suggest that
the underrepresentation of the 6.6kbp allele observed here
indicates a specific association between Ha-ras RFLP and
susceptibility to colorectal cancer and demonstrates the need
to evaluate this association for individual tumour types.
The thyroid follicular epithelial cell as a recipient for DNA
transfection
N.R. Lemoine & D. Wynford-Thomas
Cancer Biology Unit, Department ofPathology, University of
Wales College ofMedicine, Heath Park, Cardiff CF4 4XN,
UK
With the ultimate aim of developing an immortal epithelial
cell line as a test system for detection of epithelial-specific
human oncogenes by DNA transfection, we have
investigated the uptake and expression of exogenous DNA
by human thyroid epithelial (follicular) cells. Primary
cultures of normal thyroid follicular cells (free of fibroblasts
as judged by electron microscopy) were transfected in
suspension or monolayer culture by calcium phosphate co-
precipitation with a plasmid containing the SV40 genome
together with normal human carrier DNA (0.5 ,ug+20pg
respectively per 5 x l05 cells). The frequency of cells
expressing SV40 sequences was assessed 2-7 days after
transfection by immunodetection of nuclear large T antigen
using antibody PAB419 together with an indirect immuno-
operoxidase procedure. In DME/F12 medium containing
10% FCS we observed a frequency of 10-4 positive cells,
which remained unchanged for up to 7 days. Addition of
thvroid stimulating hormone (TSH) 10mUml-1, 20min
before transfection increased this tenfold to 10-3. Inclusion
of a lysosomal inhibitor ammonium chloride (20mM)
resulted in a further improvement to 2 x 10-3. These results
support our hypothesis that the unusual phagocytic property
of the thyroid follicular cell when stimulated by TSH may
make this an especially suitable epithelial cell for
transfection. We are currently exploring the frequency of
stable expression using this system.
Optimisation of the NIH3T3 focus assay for detection of
activated oncogenes
N.R. Lemoine, V. Wynford-Thomas & D. Wynford-Thomas
Cancer Biology Unit, Department of Pathology, University of
Wales College ofMedicine, Cardiff, UK.
Although DNA mediated induction of transformed foci in
NIH3T3 monolayers has been widely used as an assay for
activated oncogenes in human tumours, its usefulness has
been limited by a high and variable incidence of background
spontaneous foci. We set out to correct this by examining
the influence of (a) serum concentration, (b) feeding interval,
(c) medium composition and (d) plastic surface, on (i) the
incidence of spontaneous foci, and (ii) the incidence of true
foci induced by transforming sequences, using plasmid
pSV2neoEJ containing activated Ha-ras as a positive control.
Using 'high background' NIH3T3 cells (which had been
serially-passaged for 6 months) in standard culture
conditions - 5% calf serum (CS), with a 3 day feeding
interval using DME medium on 90mm Nunc dishes - we
observed a spontaneous focus incidence of 20/dish and a true
focus incidence of 21/dish. (a) Simply adjusting the serum
concentration was not successful since concentrations below
5% failed to support a viable monolayer while higher
concentrations increased the spontaneous focus rate. (b)
Keeping the serum concentration at 5% but reducing the
feeding interval to 1 day, however, dramatically reduced the
spontaneous focus incidence (to 0/10 dishes) giving a
reproducibly uniform monolayer. Furthermore the true rate
was improved to 55/dish. (c), (d) Use of a 'richer' medium
(DMEM: F12/1:1) and Falcon dishes both gave further
improvements in the true focus rate (up to 154/dish) with no
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Our results demonstrate a dramatic improvement in the
'signal to noise' ratio of the focus assay by simple
adjustment of culture conditions without recourse to
recloning.
Heterogeneity of c-myc expression in human tumour cells
detected by in situ hybridisation
J. Boultwood, E.D. Williams & D. Wynford-Thomas
Cancer Biology Unit, Department ofPathology, University of
Wales College ofMedicine, Cardiff' UK.
In situ hybridisation represents a useful complementary
technique to Northern blotting for analysis of oncogene
expression in human tumours since it offers the potential to
detect aberrant expression in minor subpopulations of cells.
Comparison of the various techniques available using the
promyelocytic leukaemia cell line HL60 (which is known to
overexpress c-myc) demonstrated the superiority of single
stranded c-RNA probes generated by SP6 polymerase. Using
32P labelled c-myc cRNA and emulsion autoradiography we
observed an unexpected heterogeneity in expression of this
oncogene in asynchronous, undifferentiated HL60 cultures.
While the majority showed a range of intensities (from 10-
100 grains/cell after 7 days exposure), 20% of cells were
intensely labelled (>200 grains/cell) whereas 20% were
indistinguishable from background (<3 grains/cell). In a
preliminary study of medullary carcinoma of the thyroid,
using both frozen and paraffin sections. c-myc was not
detectable above the background, non specific signal (<3
grains/cell) in 4 out of 5 tumours, and in normal thyroid and
other control tissues. One case, however, was clearly positive.
In this tumour, while a weak signal (10-20 grains/cell) was
observed over the majority of the cells, one nodule
(representing -10% of the total tumour area observed in
the section) was intensly positive (>200 grains/cell). These
examples of heterogeneity of oncogene expression clearly
demonstrate the additional information which can be
obtained by in situ compared with homogenate-based
hybridisation.
Measurement of 5-methylcytosine in DNA
J. Catania', B.C. Keenan2, G.P. Margison
& D.S. Fairweatherl
'Department ofGeriatric Medicine, Withington Hospital and
2Department ofCarcinogenesis, Paterson Institutefor Cancer
Research, Manchester M20 9BX, UK.
5-methylcytosine (5-MeC) in DNA may be involved in the
control of eukaryotic gene expression (A. Razin & A.D.
Riggs, Science, 210, 604 (1980)). Quantitation of this product
involving the degradation of DNA to purine and pyrimidine
bases has been inaccurate because deamination of cytosine
and 5-methylcytosine occurs during the hydrolysis procedure
(J.P. Ford et al., J. Biol. Chem., 255, 7544 (1980)). We have
therefore undertaken a systematic study of the hydrolysis of
DNA by hydrofluoric acid (HF). Separation of the bases
was achieved using a Nucleosil 5 SB column eluted with
10mm sodium acetate pH 4.0 containing 30% methanol, and
quantitation at 280nm was by automated peak area
integration. Deoxycytidine and 5-methyldeoxycytosine were
shown not to undergo detectable levels of deamination
during prolonged periods (up to 24h) at 80"C in 48% HF.
Kinetic studies showed that the release of purine and
pyrimidine bases was complete by 4h under these conditions.
Analysis of the 5-MeC content of DNA from Herring testis
and Calf thymus gave 5-MeC levels of 9.62% and 6.67%
respectively i.e. very close to the literature values of 10.8%
and 6.6% (G.D. Fasma (ed.), Handbook of Biochemistry and
Molecular Biology, 3rd Edn. p. 241 (1976)). This method is
ideally suited for the determination of the overall cytosine
methylation levels in DNA. (HF is hazardous)
The ras oncogene and metastasis
J.S. Wallace, A.J. Hayle, A.J. Syms, M. Evans, D. Tarin
& K.A. Fleming
Nuffield Department ofPathology, University ofOxford, John
Radcliffe Hospital, Oxford OX3 9DU, UK.
Transfection of cells with cloned genes or total genomic
DNA offers opportunities for studying the regulatory
disturbances responsible for aspects of neoplastic behaviour.
We have used this method to examine whether incorporation
of the cloned 6.6kb fragment of the mutated c-Ha-ras
human oncogene into the genome of 3T3 fibroblasts can
confer metastatic capability on these cells. 3T3 cells co-
transfected with the mutated ras gene and the neomycin
resistance plasmid psv2-neo were selected by culture in
neomycin. On subcutaneous inoculation into MFI nude mice
these cells proved to be tumorigenic with short latent periods
(- 14 days). However, there was no evidence of spontaneous
metastasis at autopsy, or on histological examination of the
lungs and other organs, 90 days after inoculation.
Intravenous inoculation of cells transfected with ras showed
that they were clonogenic in the lungs but cells transfected
with psv2-neo alone were not. Successful incorporation of
the oncogene into the clones obtained by neomycin selection
was confirmed by Southern blotting and expression was
demonstrated by immunoprecipitation of the ras protein.
The results in this experimental system indicate that
transfection of a mutated ras oncogene into non-neoplastic
3T3 cells is not by itself sufficient to initiate spontaneous
metastatic behaviour but can make the cells tumorigenic and
capable of colonising the lungs if they are inoculated intra-
vascularly.
Phenotypic heterogeneity of B-cell antigen expression and
HLA class II antigens in B-cell-non-Hodgkin's lymphoma
(B-NHL)
D.B. Jones, K. Moore' & D.H. Wright
University Department ofPathology and 1Regional
Immunology Service, General Hospital, Southampton
S09 4XY, UK.
We describe the results of an investigation in frozen section
of 50 cases of B-NHL with a panel of 15 monoclonal
antibodies directed to B cell surface antigens and to HLA
sublocus products. As a group, B cell tumours displayed a
considerable variation in staining intensity with different B
cell surface antigens and this was also apparent between
tumours of the same histological type. Heterogeneity was
also apparent when cases of B-NHL were examined with
antibodies identifying different epitopes of a single surface
molecule. This type of heterogeneity was most marked with
antibodies directed towards the CD22 antigen widely
expressed on normal B cells. Functional expression of
different CD22 epitopes, therefore, varies in neoplastic cells.
Antibodies specific for the HLA Class II sublocus products,
DP, DR and DQ, all generally expressed on normal B cells,
similarly showed heterogeneity in B-NHL: commonly, the
loss of a single sublocus product from the tumour cell
surface or, rarely, the expression of one sublocus product
only. These data indicate that in B-NHL the tumour
population does not always mimic exactly, in phenotype, the
equivalent normal B cell population and has implications in
the construction of monoclonal panels for the routine
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Analysis of sugar specific cellular glycoproteins from Hodgkin
lymphoma and other lymphoma/leukaemia cell lines
D.J. Flavell, D.B. Jones & D.H. Wright
Department ofPathology, Southampton General Hospital,
Southampton S09 4XY, UK.
Studies aimed at determining the histogenesis of the Reed-
Sternberg cell, the putative neoplastic cell of Hodgkin's
lymphoma, have been hampered in the past by difficulties
encountered in preparing pure suspensions of such cells.
Recently however, a number of cell lines derived from
Hodgkin involved tissue have become available and whilst it
is not certain that these genuinely represent the Reed-
Sternberg cell population, they do share certain
characteristics in common with their in vivo counterparts. We
have undertaken to analyse by SDS-polyacrylamide gel
electrophoresis (PAGE), Western blotting and lectin probing,
the cellular glycoprotein profiles of four Hodgkin cell lines
(L428 and L591, Diehl et al., Cancer Treatment Rep., 66,
615, 1982; Ho and Co; Jones et al., Haematol. Oncol., 3, 133,
1985) and compare these with profiles obtained for cell lines
of established lymphoid, myeloid or monocytoid origin. Six
1251 labelled lectins representing the most common
carbohydrate specificities were used to probe nitrocellulose
membranes of SDS-PAGE separated detergent solubilised
cellular glycoproteins for each cell line studied. Lectins
binding to specific bands were visualised by autoradiography
and molecular weights (Mr) calculated by reference to a
standard calibration curve. The complex glycoprotein
profiles obtained for the Hodgkin cell lines studied suggest
these cells to be of lymphoid origin, an observation in
agreement with both immunophenotypic and immuno-
globulin/T cell receptor rearrangement studies. Work is now
in progress to raise monoclonal antibodies against specific
glycoprotein bands of interest for use as immuno-
cytochemical probes on tissue section.
Monoclonal anti-light chain idiotype as a tumour-specific
probe for human B cell lymphoma
M. Wrightham, A.L. Tutt, M.J. Glennie, T.J. Hamblin,
G.T. Stevenson & F.K. Stevenson
Lymphoma Research Unit, Tenovus Laboratory, General
Hospital, Southampton S09 4XY, UK.
Preparation of monoclonoclonal anti-idiotype reagents for
monitoring and therapy of B cell neoplasms is dependent on
a supply of idiotypic Ig as immunogen. This is not readily
available from tumours which do not secrete or display high
levels of Ig. Such patients frequently have low levels of
urinary monoclonal light chain of neoplastic origin. The
object of this study was to investigate whether monoclonal
antibody raised against isolated light chain idiotype also
recognised determinants in intact (heavy +light chain)
idiotypic Ig, allowing urinary light chain to serve as
alternative immunogen. A hybridoma was selected secreting
antibody which recognised idiotypic A of patient L.P., but
not normal A chains by a preliminary screen, and which also
reacted with idiotypic IgMA on the patient's tumour cells.
The antibody did not recognise normal tonsil cells (immuno-
peroxidase staining) or a panel of IgMA paraproteins (direct
binding ELISA). The antibody was characterised more fully
using an ELISA system based on inhibition of antibody
binding to idiotypic light chain coated onto a solid phase by
various A-containing species in the free solution phase. By
this criterion the antibody recognised I in 2 x 104 molecules
of pooled normal A chains, confirming its specificity for a
private idiotope. The target epitope appeared to be less
available in dimeric light chain than in the monomer or
idiotypic IgM. This epitope is clearly distinct from that
recognised by another monoclonal antibody specific for
combined (heavy+light chain) idiotype, as the two showed
additive binding to IgMA L.P. in a direct binding ELISA
system. Such anti-light chain idiotype reagents should be
applicable to monitoring and possibly therapy of B cell
neoplasms.
Emergence of immunoglobulin variants following treatment of
a B-cell leukaemia with anti-idiotype: saporin immunotoxin
M.J. Glenniel, H. McBride', A.T. Worth', F. Stirpe2,
P.E. Thorpe2 & G.T. Stevenson'
1Lymphoma Research Group, Tenovus Laboratory,
Southampton S09 4XY and 2ICRF, Lincoln's Inn Fields,
London WC2A 3PX, UK.
An immunotoxin (IT) composed of monoclonal anti-idiotype
(Id) coupled via disulfide linkage to the plant ribosome-
inactivating protein saporin, has been investigated in the
treatment of guinea pig L2C leukaemia. In vitro this
conjugate remained toxic to L2C cells, as measured by the
incorporation of [3H] leucine into protein, at below 10-10M
and was respectively > 10,000 and 900 times more potent
than free saporin and saporin coupled to an antibody of
irrelevant specificity. In therapy a single s.c. injection of
reactive IT given 24h after an i.p. inoculum of 105 L2C,
increased the mean survival of animals from 15 days to 30
days. Under the same conditions control reagents, including
free saporin, anti-Id alone or saporin coupled to a non-
reactive antibody, did not prolong animal survival. All L2C
cells emerging after IT therapy showed altered immuno-
globulin (Ig) expression which rendered them non-reactive
with the IT. Predominantly L2C cells had lost p heavy chain
production leaving them negative for intracellular, surface
and secreted IgM, but still positive for idiotypic light chain
production. In addition a minor group of L2C variants did
express normal levels of IgM but with an altered or mutated
Id which rendered them non-reactive with the IT.
Our previous immunotherapy investigations using
monoclonal anti-Id alone have not revealed these Ig variants.
We suggest that it is the increased selective force exerted by
the highly potent IT which allowed non-reactive populations
to emerge. Such cells, particularly those of an Ig negative
phenotype, could prove a major obstacle to the application
of IT therapy in humans.
Anti idiotypic mechanisms lead to tumour dormancy and
protection in a murine lymphoma, BCL,
A.J.T. George & F.K. Stevenson
Lymphoma Research Unit, Tenovus Research Laboratories,
Southampton General Hospital, Southampton, S09 4XY, UK.
Idiotypic determinants on the surface immunoglobulin of B
cell tumours are tumour-associated antigens and therefore
present a target for anti-idiotypic attack. Immunization of
mice with idiotypic IgM from the syngeneic BCL1 lymphoma
has been used to generate anti-idiotypic responses and to
follow the effect on tumour development. Such
immunization protects specifically against challenge with
some mice surviving >6 months. Spleens from long-term
survivors with no macroscopically visible tumour, when
examined with anti-idiotypic antibody, showed a range of
apparently dormant tumour occupying 2-50% of the spleen.
On the passage of these spleen cells into naive mice, BCL1
tumour developed and killed the recipients in times
indistinguishable from routine tumour passage. Analysis of
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identified low levels of cytotoxic anti-idiotypic antibody in
serum and splenic T cells which proliferated specifically in
response to idiotypic IgM. Only low levels of cytotoxic T
cells were found. Passive transfer studies demonstrated a
major role for antibody in protection against tumour.
Tumour arising in immunized animals shows a variable
pattern of expression of idiotypic IgM at the cell surface,
although it was always present in the cytoplasm. Passage of
a low number of cells from one such emergent tumour
allowed the isolation of a stable variant tumour, SNAG 1,
which lacked surface idiotype and IgM. In spite of
containing cytoplasmic idiotype this variant failed to secrete
idiotypic IgM in vivo or in vitro. This study raises the
possibility of attempting a similar immunization in human
patients with low grade lymphoma who might be capable of
mounting an anti-idiotypic response.
Idiotypic immunoglobulin as an indicator of residual disease in
multiple myeloma following treatment with high dose
melphalan
J. Thompson', P. Selby2, V. Anderson3, T.J. McElwain2
& G.T. Stevenson3
1 Wessex Medical Oncology Unit, Southampton General
Hospital, Southampton; 2Royal Marsden Hospital, Sutton and
3Tenovus Research Laboratory, Southampton, UK.
Patients in apparent complete remissiont (CR) from multiple
myeloma following treatment with high dose melphalan were
monitored for residual disease using a sensitive anti-idiotype
(Id) enzyme-linked immunosorbent assay (ELISA) capable of
detecting low levels of tumour-derived idiotypic Ig. High
titre anti-Id anti-serum was prepared for each patient in
rabbits, using idiotypic myeloma Ig isolated from pre-
treatment sera as a source of immunogen. Reactivity towards
common immunoglobulin (Ig) determinants was removed by
extensive absorption against pooled human IgG and/or IgA
as appropriate, and then antibodies were affinity purified by
elution from a column of the patients' purified idiotypic Ig.
In the ELISA these purified anti-Id antibodies were used as
a coating layer to capture the patients idiotypic Ig from test
sera, before detecting with an enzyme-labelled antihuman Ig
antibody. The specificity of each anti-Id reagent was fully
established against pooled human serum and irrelevant
immunoglobulins.
Ten patients are under investigation in the current study.
All achieved CR as judged by conventional criteria,
including the absence of a monoclonal band from electro-
phoretic strips of the patients' sera. Despite these indications
the sensitive ELISA system presented has shown that in all 6
patients monitored so far, idiotypic myeloma protein
remained in the circulation throughout the post-treatment
period at levels of <l1,000 ugml- . Three of the 6 patients
have since relapsed clinically. We suggest that the monitoring
system described could be useful in evaluating CR in the
research context. (tNo detectable paraprotein in serum, no
urinary monoclonal light chain excretion and bone marrow
morphologically normal.
Intensive chemotherapy (MACOBLE) for aggressive non-
Hodgkin's disease
G.J. Forrest', D. Cunningham', T. Young', R. Moss',
I.L. Evans2 & M. Soukop'
'Department ofMedical Oncology, Royal Infirmary, Glasgow
and 2Department ofHaematology, Western Infirmary,
Glasgow, UK.
Aggressive non-Hodgkin's lymphomas have a poor prognosis
unless treated by intensive chemotherapy. Between 1983 and
1986, 53 patients (49 previously untreated) received intensive
chemotherapy with cyclophosphamide, 750mgm -2 i.V.;
adriamycin, 40mg-2 i.v.; bleomycin, 15mg i.m. on day 1,
etoposide 100mgm-2 i.v. on days I and 2; vincristine,
2mgi.v.; bleomycin 15mg i.m.; methotrexate, 300mgm-2
i.v. bolus and methotrexate, 1.2gm-2 12-hourly infusion
with folinic acid rescue on day 10. Oral prednisolone, 100mg
was also given days 1-5 q 3-weekly (MACOBLE).
Twenty-nine patients had Stage IV disease, 8 Stage III, 11
Stage II and 5 Stage I disease. Immunocytochemical markers
were performed in 36 patients (23 T cell, 13 B cell).
Twenty-two (41%) patients achieved CR with a total
response rate to chemotherapy of 75%. Median survival of
patients reaching CR has not been achieved but will be in
excess of 16 months. The median survival of patients
achieving PR or stable disease/PD was 11 months and 3
months respectively. Four patients with major PR
successfully achieved CR after radiotherapy to areas of
residual bulk disease. The major toxicity was myelo-
suppression-median WCC 1.2 x 103 mm-3 and platelet
116,000mm-3. The major prognostic indicator was achieval
of CR. T cell markers were not an adverse prognostic
indicator. The MACOBLE regimen is a useful therapy in
aggressive non-Hodgkin's lymphomas.
Treatment of refractory and relapsed non-Hodgkin's
lymphoma (NHL) with ifosfamide (I), methotrexate (M) and
etoposide (VP16)
G. Sangster & M.J. Leyland
Department ofClinical Haematology, East Birmingham
Hospital, Birmingham B9 5ST, UK.
Fourteen patients (12 male, 2 female), mean age 50 years
(range 25-68), with refractory or relapsed NHL (12
patients), chronic lymphocytic leukaemia (CLL, 1 patient) or
Hodgkin's disease (HD, 1 patient) were treated with
ifosfamide (I) 1 gm-2 day - for 5 days by 2h infusion (5
patients) or 4gm-2 by 24h infusion for 1 day (9 patients),
etoposide (VP16) 100mgm-2 day -' for 3 days by 2h
infusion and methotrexate (M) 30mgm-2 bolus on days 3
and 10. Courses of IMVP-16 were repeated every 21-38
days. Patients receiving ifosfamide 24h infusion were given
mesna (total dose 7.2gm-2) as a 36h infusion in addition to
a high fluid intake to prevent ifosfamide-induced urotoxicity.
Mesna (total daily dose 1.2gm-2) was given by bolus
injections to those patients receiving fractionated ifosfamide.
Six NHL patients had high-grade (HG), and 6 had low-
grade (LG) histology (Kiel classification). Ten/twelve NHL
patients had stage III/IV disease and 5 had bone marrow
infiltration. Prior therapy included CHOP/MTX in 11
patients. Four patients with LG and 1 with HG-NHL had
been in complete remission (CR, duration range 2 months-4
yrs) after CHOP; 7 NHL patients had progressed on CHOP
after an initial response. Two patients died of progressive
NHL and/or sepsis during the first course of IMVP-16.
Twelve patients received at least 2 courses and were
evaluable for response using standard WHO criteria. Four
patients (3 NHL, 1HD) showed progressive disease (PD)
after 2 courses and 7 patients with less than a partial
response (PR) failed to achieve PR or CR during 2 further
treatment cycles. One patient with low-grade NHL relapse in
small bowel had only minimal residual disease (local
mesenteric nodes) after surgery and has remained in clinical
CR for . 15 months. A nadir neutrophil count . 500 or
platelet count <50,000 was seen in 23/40 and 12/40 courses
respectively. Five episodes of infection associated with
neutropenia were seen. Nausea and vomiting was generally
mild and there was no urotoxicity. The results of this study
suggest that salvage therapy with IMVP-16 in HG-NHL
may have very limited value in patients who have not had a
durable response to first-line therapy.346 JOINT MEETING OF THE BACR, EACR AND THE RSM
Management of localised (stage I+II) non-Hodgkin's
lymphoma (NHL)
R.E. Taylor, S.G. Allan, G.L. Ritchie, G.R. Kerr,
J.F. Smyth & R.C.F. Leonard
Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
Between Jan. 1974 and Dec. 1983, 177 patients (113 high
grade and 64 low grade) stage I+II NHL were treated with
surgical excision alone (4 patients) or excision/biopsy
combined with irradiation (125 patients), chemotherapy
(24 patients) or both (24 patients). Seventy-five (42.4%)
presented with nodal and 102 (57.6%) with extra-nodal
disease. Actuarial survival for stage I patients was 75.2% at
5 years and 71.7% at 10 years and for stage II patients
64.3% at 5 years and 58.9% at 10 years. For patients with
stage II and bulky (.5cm) stage I, and gastrointestinal, high
grade NHL, there was a non-significant trend towards
prolongation of survival +RFS for patients treated with
chemotherapy alone or together with irradiation, compared
with irradiation alone. For patients responding completely to
chemotherapy, irradiation of bulky sites did not appear
necessary. For irradiated patients, local control was achieved
in 51/57 (89%) with low grade and 79/91 (87%) with high
grade NHL, and for bulky high grade NHL in 31/40 (77.5%)
treated with <40Gy and 6/6 (100%) with _40Gy. There
was no advantage for extended compared with involved
fields. Survival was significantly prolonged for low grade
compared with high grade patients, for patients aged <60
and for those with a complete response to primary therapy.
For extranodal NHL, actuarial survival at 5 years was 80%
for thyroid, 87.5% for low grade and 42.5% for high grade
gastrointestinal, and 82.4% for stage I and 0% for stage II
Waldeyer's ring.
A study of the gastro-intestinal tract in patients with B cell
neoplasms
G. Smith', I. Chesner3, J. Crocker2, M.J. Leyland'
& P. Asquith3
'Department ofHaematology; 2Department ofHistopathology
and 3The Metabolic Unit, East Birmingham Hospital,
Bordesley Green East, Birmingham, UK.
A review of data collected at this hospital from patients with
chronic lymphocytic leukaemia (CLL) and non-Hodgkin's
lymphoma (NHL) suggested that iron deficiency was a
common finding. In order to evaluate the cause, fifteen
patients with CLL and NHL, not primarily of gastro-
intestinal origin, were extensively investigated in the
Metabolic Unit. Standard tests of absorptive function were
performed together with endoscopy, sigmoidoscopy and
aspiration of duodenal contents. Duodenal juice was sent for
bacterial culture and estimation of immunoglobulin levels. A
lactulose hydrogen breath test was also performed. Gastric,
duodenal and rectal biopsies were stained using immuno-
gold-silver staining (IGSS) technique. This immunostaining
method has much enhanced sensitivity for demonstrating
antigens in paraffin sections as compared with peroxidase-
anti-peroxidase methods, and reliably stains surface as well
as cytoplasmic immunoglobulin. Using this technique, seven
patients were clearly demonstrated to have infiltration of the
gastrointestinal mucosa by monoclonal B cells at one or
more sites. Six patients were found to be iron deficient with
impaired iron absorption. Five of these had gastrointestinal
involvement. The hydrogen breath test indicated bacterial
contamination of the small intestine in nine patients. This
has been confirmed by positive culture of duodenal contents
in four cases. There was associated hypogamma-
globulinaemia in four cases. We conclude that occult
involvement of the gastrointestinal tract is a common finding
in patients with B cell neoplasms and is associated with
impaired absorptive function and possibly impaired mucosal
immunity.
Non-Hodgkin's primary lymphoma of the gastrointestinal tract
R.R. Moss', S. Allan3, T. Young', R. Taylor3,
D. Cunningham', G. Forrest', R.F. Leonard3, M. Soukop'
& S.B. Kaye2
'Department ofOncology, Glasgow Royal Infirmary;
2Department of Oncology, Western Infirmary, Glasgow and
3Department ofOncology, Western Infirmary, Edinburgh, UK.
A study was made of 81 patients with primary gastro-
intestinal lymphoma. Forty-four per cent of tumour occurred
in the stomach or duodenum; 44% in the small bowel or
mesentery; 5% in the colon or rectum; 2% in the ileocaecal
region. In the remainder it was not possible to determine the
site of origin. The Rappaport histological classification was
used. The commonest histological subtype was diffuse
histiocytic (48%). This group had a poor prognosis with a
median survival of 14 months; in contrast, the lymphocytic
lymphomas fared better, irrespective of nodularity or
differentiation. The patients were staged according to the
system proposed by Blackledge. Stage I had the best
prognosis (5-year survival 73%); in contrast, there were no
stage 4 5-year survivors. Eighty-four per cent of patients had
some form of surgical resection; prognosis was better in
those where the resection was complete. The majority of
patients received in addition radiotherapy or chemotherapy;
survival in the surgery/radiotherapy group was better than
in the surgery/chemotherapy group. Overall 5-year survival
was 43%.
Increasing incidence of oesophageal carcinoma; in which sites
and which histological types?
J. Powell, J.E. Robertson & C.C. McConkey
Clinical Cancer Monographs, Regional Cancer Registry, Q.E.
Medical Centre, Birmingham B15 2TH, UK.
Oesophageal carcinoma is such a rare tumour (5 per
100,000) that population based studies on changes in the
incidence by both sub-site and histology have not hitherto
been possible. In a study of 6,398 cases occurring in the
West Midlands Region over the 25 year period 1957-1981
the numbers were sufficient to enable marked differences to
be observed within classifications by both parameters.
The categorisation by site was into upper, middle and
lower thirds. Tumours of doubtful origin were reviewed and
those arising in either the hypopharynx or cardia were
rigorously excluded. It was not possible to specify a subsite
within oesophagus for - 12% of the cases, but as this
proportion has remained relatively constant throughout the
period it is unlikely to have introduced any bias. The
histological breakdown was into squamous, adenocarcinoma,
anaplastic and 'no histological confirmation' (30%). To
compensate for changes in the age structure of the
population, age-standardised incidence rates were used.
Results indicate a steady increase in incidence of the
middle and lower thirds for both sexes. Tumours of the
upper third and of unspecified site remained relatively stable,
indicating that this increase is a real one and not the result
of changes in classification. The increase in the middle third
occurred in squamous and in adenocarcinomas and in both
sexes. In anaplastic carcinomas the increase was only in
females. In the lower third there was an increase inJOINT MEETING OF THE BACR, EACR AND THE RSM 347
squamous cell carcinoma in women but not in men. For
adenocarcinomas the rates increased in both sexes and was
highly significant in men. Anaplastic carcinomas showed
little change.
Properties of a breast carcinoma associated antigen defined by
the monoclonal antibody NCRC-11
M.R. Price, G. Crocker, S. Edwards & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham, NG7 2RD, UK.
Inflammatory or malignant infiltration of rectal tumours -
Is there an alternative to digital assessment?
J. Beynon, D.M.A. Foy, J.L. Channer, J. Virjee &
N.J.McC. Mortensen
Departments of Surgery, Medical Physics, Pathology and
Radiology, Bristol Royal Infirmary, Bristol BS2 8HW, UK.
Malignant fixation in rectal tumours is associated with a
worse prognosis and particularly a higher incidence of local
recurrence. Distinguishing between these two types of
fixation by digital examination may be difficult. Using
endoluminal ultrasonograph) (ELU) we have compared pre-
operative ultrasonic measurements of the depth of the
invasion with histopathological estimates of depth measured
from both prepared sections and operative specimens.
Ultrasonic examinations were performed with a rotating
endoprobe using 5.5 MHz and 7.0 MHz transducers, selecting
images at the site of maximum depth of tumour. In 35
patients a comparison of ELU tumour depth was made with
maximum depth measured from the histological section. The
coefficient of correlation was 0.63 (P<0.001). In 27 patients
it was possible to compare ELU with tumour depth
measured from the resected specimen, coefficient of
correlation - 0.80 (P <0.001). Pre-operative ELU
assessments of the depth of invasion of rectal tumours are
accurate when compared with histology. ELU may thus
provide an objective method for differentating between
inflammatory and malignant infiltration.
Endosonography for the assessment of para-rectal lymph node
involvement in rectal cancer
J. Beynon, D.M.A. Foy, J.L. Channer, N.J.McC. Mortensen
& J. Virjee
Departments ofSurgery, Medical Physics, Pathology and
Radiology, Bristol Royal Infirmary, Bristol, BS2 8HW, UK.
Assessment of para-rectal lymph node involvement in rectal
cancer continues to be a problem. Previous studies have
shown digital examination correctly identifies only 50% of
involved lymph nodes while computer tomography is also
disappointing in this field. Endoluminal rectal ultrasound has
been used to assess the involvement of pararectal lymph
nodes in 66 patients with primary rectal cancer.
Examinations have been performed with a rotating
endoprobe and 5.5 MHz and 7.0 MHz transducers.
Subsequently 57 resections were performed and histological
assessment compared with ultrasonic data. Sonographically,
involvement was correctly predicted in 22 cases with 7 false
positives, while 24 cases were negative with 4 false negatives.
The coefficient of correlation between ultrasonic examination
and histopathology was 0.62 (P<0.001). The accuracy for
predicting lymph node metastases was 81%, the sensitivity
85%, specificity 77% and the predictive value 76%.
Endoluminal rectal ultrasound is an accurate method of
assessing pararectal lymph node involvement in rectal cancer
and its use pre-operatively enables a more accurate staging
to be performed.
NCRC-11 is an anti-human breast carcinoma monoclonal
antibody which defines a high mol. wt glycoprotein antigen
(>400 kD) and the expression of this antigen in breast
carcinomas correlates with patient survival (Ellis et al., Br.
Med. J., 290: 881, 1985). The antigen has been purified from
detergent extracts of breast carcinomas by immunoadsorbent
chromatography, and shown to be a wheat germ agglutinin-
binding glycoprotein, which is susceptible to proteolysis with
pepsin or papain although NCRC-11 antibody binding is
unaffected by heat (100°C for 5 min) or neuraminidase
treatment. In addition to its presence in tumours, the
NCRC-11 antigen is also a product of specialized normal
epithelia (being particularly associated with luminal surfaces
of secretory epithelia), although in healthy individuals it is
not found in the circulation. However, in breast cancer
patients, the breast tissue architecture is disrupted sufficiently
by the developing tumour to allow products from the
tumour to have access to the circulation. Thus, NCRC-11
antigens have been identified in breast cancer patients' serum
both by immunoblotting techniques and by sandwich radio-
immunoassay. The findings indicate that the NCRC-11
antigen has potential as a diagnostic and prognostic marker
in breast cancer.
Expression of histocompatibility antigens and characterisation
of mononuclear cell infiltrates in human renal cell carcinomas
M.O. Symes, D. Heinemann & P.J.B. Smith
Departments ofSurgery and Urology, University ofBristol,
UK.
Neoplastic tissue was obtained at operation from 10 renal
cell carcinomas, from the adjacent normal kidney in 6 cases
and from I other normal kidney. The biopsies were snap
frozen in liquid nitrogen and sections were subsequently
stained with monoclonal antibodies against major histo-
compatibility complex antigens, Class I and II, and several
types of mononuclear cell, by the indirect immunoperoxidase
method. The degree of staining was graded from heavy 4,
through moderate 3, few 2, occasional 1, to nil 0. MHC Ag
were consistently expressed, grad 3-4, by the glomerular
basement membranes and proximal convoluted tubules of
normal kidney, but were absent in 8 of 10 carcinomas. There
was a grade 3-4 mononuclear cell infiltration in the stroma
of normal kidney and between the carcinoma cells which was
composed principally of macrophages. However, in the two
carcinomas expressing MHC Ag there was a grade 2-3
infiltration with T lymphocytes. The absence of MHC Ag on
carcinoma cells mitigates against attempts to potentiate the
patient's immune response to his tumour, e.g. by renal artery
embolisation.
Effector cell populations in antibody-dependent cellular
cytotoxicity (ADCC)
R.J. Dearman, M.J. Glennie & G.T. Stevenson
Lymphoma Research Group, Tenovus Laboratories, Tremona
Road, Southampton, S09 4XY, UK.
We have investigated the principal effector cells in human
peripheral blood capable of lysing neoplastic B cells (guinea348 JOINT MEETING OF THE BACR, EACR AND THE RSM
pig L2C) coated with various anti-idiotype (Id) antibodies
(Abs). In addition to conventional monoclonal and
polyclonal Abs we have employed a range of chimeric
univalent Abs consisting of Fab'y from monoclonal anti-Id
covalently coupled to Fc fragments derived from human,
rabbit or guinea pig IgG. These derivatives have the
advantage of being univalent and therefore non-modulating,
and of having interchangeable Fc zones on the one Ab
Fab'y.
Our results suggest that human peripheral blood
mononuclear cells contain two populations capable of
mediating ADCC. First, a population of non-adherent
lymphocytes which were cytotoxic with Abs and Ab
derivatives bearing human, rabbit or guinea pig Fc regions,
but not with the mouse monoclonal Abs. The performance
of these cells was considerably enhanced following overnight
pre-incubation in human recombinant interferon y (yIFN),
but was abolished by addition of a monoclonal Ab (3G8)
which binds and blocks the Fcy receptors on human
lymphocytes. The second effector population probably
contained largely monocytes and was only cytotoxic with
mouse monoclonal Abs. Monocyte depletion of effectors by
adherence to plastic considerably reduced the cytotoxicity of
all monoclonal Abs. Furthermore, and again in contrast to
the Abs bearing human, rabbit or guinea pig Fc regions,
ADCC by monoclonal Abs was not enhanced by yIFN
treatment and was not blocked by the Ab 3G8. Together
these results point to two discrete ADCC effector
populations: A lymphocyte population which can lyse target
cells coated with human, rabbit and guinea pig Abs; and a
monocyte population which can recognise mouse Abs.
Role of MHC class I antigens and the CD3 complex in the
lysis of autologous human tumours by T cell clones
T.E. Roberts, U. Shipton & M. Moore
Department ofImmunology, Paterson Institutefor Cancer
Research, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
Peripheral blood lymphocytes (PBL) of 4 patients with
malignant effusions were stimulated for 6 days with purified
autologous tumour cells, before isolation of the lymphoblasts
and cloning by limiting dilution in interleukin-2 (IL2). Forty-
five clones were analyzed for cytotoxicity (CTX) against
autologous, allogeneic and cell-line targets of known status
with respect to expression of major histocompatibility
complex (MHC) antigens, estimated by reaction with the
W6/32 (anti HLA, -A, -B, -C monomorphic) and
TDR31.1 (anti HLA-DR) monoclonal antibodies (McAb).
Twenty-one of the 45 clones were cytotoxic, 7 for the
autologous target only, the remainder exhibiting various
degrees of activity against allogeneic and cell-line targets as
well. All clones were CD3+. Autologous CTX was almost
always inhibited with W6/32 and OKT3 and allogeneic CTX
was also inhibited by these McAbs in some, but not all,
effector:target combinations. By contrast anti-K562 activity
was never inhibited. The data suggest that to accomplish
lysis of autologous and allogeneic targets certain clones
require MHC recognition and a functional CD3 complex,
while for others with similar target cell repertoires, there is
no such requirement. Differential inhibition by W6/32 and
OKT3 against autologous and allogeneic targets and K562
indicates that separate receptors are involved in the
recognition of fresh tumour and cell-line targets.
It is possible that T cell clones responding to a tumour-
associated antigen (TAA) in the context of self MHC
antigens can also respond to an allogeneic class I product in
the absence of TAA; and/or that aberrant class I antigen
expression on autologous tumours accounts for the
alloreactivity.
Abnormally fucosylated haptoglobin in cancer sera
S. Thompson & G.A. Turner
Department ofClinical Biochemistry, The Medical School,
Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
Serum protein-bound fucose is frequently elevated in cancer
patients (Turner et al., J. Clin. Pathol., 38, 588, 1985).
Possible explanations include the increased production of
pre-existing serum glycoproteins and/or alterations in their
sugar moieties. The acute phase proteins are known to be
elevated in cancer but it is not clear if their gylcosylation is
at all altered. We have developed a new method for the
removal of fucoproteins from normal and cancer sera using
fucose-binding lotus-lectin coupled to agarose. Isolated
fucoproteins are eluted from the lectin-agarose using 0.5M
fucose or 5% sodium dodecyl sulphate. They are then
analysed by electrophoresis and silver staining. Of several
consistent changes in the cancer sera the most striking is a
large increase in a component of approximate molecular
weight 41,000kd, especially in patients with more advanced
cancers. Two dimensional electrophoresis shows that this
component is not cxl-acid-glycoprotein and that it appears to
be most similar to haptoglobin although slightly more basic.
The identity of this molecule as fucosylated haptoglobulin is
confirmed by Western blotting. We would suggest that this
abnormally fucosylated form of haptoglobulin could be a
useful tool in the clinical diagnosis of cancer patients.
Comparison of 10 monoclonal antibodies to high molecular
weight glycoprotein (MAM-6, EMA) by means of
immunohistochemical large scale study
St. Zotterl, A. Lossnitzerl, K.D. Kunzel, Ph.C. Hageman2,
J. Hilkens2, J. Peterse3 & J. Hilgers2
'Inst. Path. Anat., Medical Academy, Dresden, GDR-8019;
2Dept. Tumour Biology and 3Dept. Pathology, The
Netherlands Cancer Institute, Amsterdam, NL-1066 CX.
Controversial data have been reported on the specificity of
monoclonal antibodies (MoAbs) against the epithelial
membrane antigen (EMA). In order to shed light on this
problem, 10 MoAbs have been compared for their reactivity
on serial sections of 165 formalin fixed and paraffin
embedded tumours using the indirect immunoperoxidase
technique. The MoAbs investigated were: antibodies to
MAM-6 (epitopes a-f), HMFG-1 and HMFG-2 (provided by
J. Taylor-Papadimitriou), NCRC-l1 (M. Price), DF3 (D.
Kufe) and E29 (anti-EMA, Dako). The tissue sample,
consisted of 115 epithelial tumours (lung, breast, squamous
tissue, colon, stomach, parotid gland, prostate gland, urinary
bladder, kidney, ovary, uterus), 10 melanomas, 15 sarcomas,
10 brain tumours and 15 malignant lymphomas. All the
antibodies proved to be useful reagents for the detection of
epithelial tissue (between 80 and 95% of the specimens).
However, the cross-reactivities observed with several
sarcomas (preferentially those of myogenic nature) and with
some lymphomas varied strikingly among the antibodies, the
commercially available E29 being one of the MoAbs giving
rise to most cross-reactions. Moreover, different staining
patterns were observed on epithelial neoplasms stressing the
different epitope (antigen?) specificity of the antibodies.JOINT MEETING OF THE BACR, EACR AND THE RSM 349
Ribonucleotide reductase M1 subunit as a marker of cellular
proliferation
G.J. Mann1, E.A. Musgrove' & L. Thelander2
'Ludwig Institutefor Cancer Research, Sydney Branch,
University ofSydney, NSW 2006, Australia and 2Department
ofBiochemistry 1, Karolinska Institute, S-104 01 Stockholm,
Sweden.
Ribonucleotide reductase catalyses the first unique, rate-
limiting step in DNA synthesis. We have measured the cell-
cycle variation of its M1 subunit using a monoclonal
antibody (Engstrom et al., EMBO J., 3, 863, 1984) and
indirect immunofluorescence flow cytometry in para-
formaldehyde-fixed cells, with simultaneous measurement of
DNA content. In logarithmically growing cultured cells (e.g.
CCRF-CEM lymphoblasts) M, is present throughout the
cell cycle in proportion to cell size. In contrast, there is no
detectable M1 in freshly isolated peripheral blood
mononuclear cells (PBMC), but it appears within 24h of
mitogen stimulation. M1 declines to very low levels in
cultures grown to limiting density (B16 melanoma), the
reduction being largely confined to cells with 2n (GO/Gl)
DNA content. HL-60 promyelocytic leukaemic cells, induced
to terminally differentiate by dimethyl sulphoxide or 12-o-
tetradecanoylphorbol-13-acetate, showed a similar marked
decrease in M1 content concomitant with the cessation of
cell division. When logarithmically growing CCRF-CEM
cells and fresh PBMC were mixed in varying proportions it
was possible to discriminate between the two cell types
according to the presence or absence of M1. We conclude
that this protein is retained during G1 and only disappears
when continuous cycling ceases (i.e. in Go cells). Its presence
may thus more completely indicate the proportion of cycling
cells (i.e. the growth fraction) in a mixed population than
conventional, DNA labelling, techniques. Since Ml may be
detected without the prior administration of any agent (3H-
thymidine or bromodeoxyuridine), its measurement should
be valuable in in vivo studies of tumour cell kinetics.
The detection of drug resistant tumour cells using flow
cytometry
A. deFazio, E.A. Musgrove, N. Heneine
& M.H.N. Tattersall
Ludwig Institutefor Cancer Research, University ofSydney,
Sydney, NSW 2006, Australia
Evidence suggests that drug resistance in tumours frequently
arises as a consequence of spontaneous somatic mutation
(Goldie & Coldman, Cancer Treatment Rep., 63, 1727, 1979).
The measurement of mutation frequency could therefore be
useful in cancer management as an index of the tumour's
potential to become resistant to therapy, Because current
techniques for cloning human solid tumour cells manifest
low cloning efficiencies, they are unsuitable for the detection
of rare spontaneous mutants. An alternative approach to this
problem is the use of the thymidine analogue 5'-
bromodeoxyuridine (BrUdR). Cells that continue to
proliferate, i.e. incorporate BrUdR, in the presence of a
selective agent are immunofluorescently stained using our
anti-BrUdR monoclonal antibody. This small proportion of
resistant cells is quantitated flow cytometrically. 6-
Thioguanine (6TG) resistance, usually attributed to a lack of
the enzyme hypoxanthine phosphoribosyltransferase
(HPRT), was measured in two cell lines, CCRF-CEM
(human T-cell leukaemia) and L1210 (mouse T-cell line). The
frequency of BrUdR positive cells, after treatment with 6TG,
was found to be 3.0 x 10 and 3.3 x 10 respectively. The
biological significance of the BrUdR positive cells was
validated by pre-treatment of cell samples with HAT
medium, thus removing the HPRT population, and by
comparison with results from cloning assays. The method
has been successfully used with tumour cell lines and its
application to human tumours is being assessed.
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